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Abstract

The Influence of Direct-to-Consumer Advertising: Who Will Talk to Their Doctor as A
Result of Prescription Drug Advertisement?

By Hai D.B. Chen, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2005
Thesis Committee:
Chair of Committee, Dr. Norman V. Carroll, Professor of Pharmacy Administration
Dr. Michael A. Pyles, Assistant Professor of Pharmacy Administration
Dr. Donna K. McClish, Associate Professor, Department of Biostatistics
OBJECTIVES:
To identify the types of patients who talk with their physicians as a result of Directto-Consumer (DTC) advertising.
METHODS:
Data were taken from a national survey, “Public Health Impact of Direct-toConsumer Advertising of Prescription Drugs, July 2001- January 2002”, conducted by
researchers from Harvard Medical School. Participants (n = 3000) were interviewed by
telephone. We constructed a conceptual framework consisting of outcomes (3 types of
physician visits), intervention (DTC experience) and five groups of explanatory factors
(health beliefs, demographics, health status, socioeconomic status and market factors).
Data were analyzed with three multivariate stepwise logistic regressions. The three
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dependent variables were whether an advertisement for a prescription drug had ever
prompted the patient to: 1) visit to discuss prescription drug, 2) visit to discuss new
condition, and 3) visit to discuss treatment change.
RESULTS:
Out of all independent variables, only six variables consistently showed significant
effects on the three dependent variables after adjusting for other variables. They were: 1)
taking medication on regular basis, 2) having anxiety, 3) having high advertisement
attentiveness, 4) viewing media as the most important source prompting one to talk with
physician, 5) believing that DTC advertisements increased awareness of new treatment,
and 6) believing that DTC advertisements improved discussion with health professionals.
The six variables were the strongest predictors for DTC-prompted physician visits.
CONCLUSIONS:
Our nationally representative study found multiple factors were associated with
different types of physician visits prompted by DTC advertisements. This information
could be used to target those patients most likely to talk to their physicians as a result of
DTC advertisements.
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CHAPTER 1
INTRODUCTION

In 2003, the pharmaceutical industry was estimated to spend over $3 billion on
direct-to-consumer (DTC) advertising in the United States and spending on DTC
advertisements quickly climbed between 1996 and 2003. (IMS, 2004; Rosenthal, 2002)
Some research attributed the escalated DTC advertising expenditure to the relaxation of
regulation from the Food and Drug Administration (FDA) in 1997. (Rosenthal, 2002;
Kaiser, 2001; Joel, 2001;Weissman, 2003) However, it was only part of the story. Many
driving forces were behind the increases in DTC advertising. Over the last two decades,
great changes occurred in the U.S. health care system.

These changes contributed

substantially to the growth of DTC advertising.

Driving forces behind DTC advertising
In addition to FDA regulation relaxation, several forces facilitated the growth of
DTC advertising in the healthcare market.

More flexible drug formularies
According to Academy of Managed Care Pharmacy (AMCP), a drug formulary is
“a continually revised list of prescription medications which represent the current clinical
judgment of providers in hospitals, health plans, and physician groups under contract with
health plans.” (AMCP, 2002) It is an essential tool utilized by managed care to control
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drug costs and ensure appropriate drug therapy. With closed or single-tier formularies, the
plans only cover certain drugs. If plan enrollees want to use prescription drugs not on
formularies, they are required to pay out-of-pocket for the entire cost of those medications.
As limited or tightly controlled drug formularies have been responsible for considerable
dissatisfaction among patients and physicians, more health plans are shifting their
formularies from single-tier or 2-tier to 3-tier formularies. (Briesacher, 2004) According to
the Annual Employer Health Benefits Survey by Kaiser, the use of 3-tier drug plans has
nearly doubled in recent years, from 29% of covered workers in 2000 to 57% in 2002. It
was reported that currently no more than half of health maintenance organizations (HMOs)
and only 10% of employer-sponsored health plans use closed formularies. (Carroll, 2002)
Many plans applied 3-tier formularies to loosen their restrictions and improve drug
coverage by requiring patients to pay more out of pocket. In contrast to single-tier
formularies which normally only cover certain drugs, 3-tier formulary systems cover a
broader range of drugs, but may require patients to pay higher copays.

Three tier

formularies set the lowest co-payment for generic drugs, a higher co-payment for
formulary or preferred brand name drugs, and the highest co-payment for non-formulary
brand name drugs. (Briesacher, 2004) Consumers are informed of differential co-payments
and given the option to pay more to receive drugs in higher tiers. Therefore, as formularies
became less restrictive and managed care shifted more drug costs to patients, patients have
become more engaged and conscious of physicians’ prescribing decisions and have started
to seek alternative information sources to support their medical decisions. (Hunt, 1998)
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Getting health information from DTC advertisements is potentially one of the choices.
(FDA, 2001)

Restrictions in promotion to physicians
Today, managed care organizations (MCOs) have brought in new policies for drug
selection. These policies require that new products demonstrate either cost advantages or
therapeutic advances over existing therapies. They limited physicians’ ability to prescribe
expensive prescription drugs through a number of mechanisms, including higher co-pays,
generic substitution, and drug utilization review. (Hunt, 1998) These policies have placed
pressure on drug manufacturers and made it more difficult for them to promote their
products to physicians, especially those with little therapeutic advantage or those that treat
“life-style” conditions, such as baldness or obesity. (Hunt, 1998)

DTC advertising

provides a way to stimulate demand for these products, especially when they possess
milder side effects or easier dosing forms. Therefore, as formularies become more flexible
in allowing patients to choose their preferred drugs, patients can help the industry break
physician’s static prescribing patterns by asking for new drugs directly.

Changes in the FDA regulation
Since 1962, the FDA has regulated the advertising of prescription drug products
under the Federal Food, Drug, and Cosmetic Act and related regulations. In Section 502(n)
of the Act, there were two key provisions on labeling and prescription drug advertising.
One was “brief summary” and the other one was "fair balance". “Brief summary” meant
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labeling must include "such information in brief summary relating to side effects,
contraindications, and effectiveness.” (FDA, 1999) In fact, the summary was not “brief”.
It typically required several pages. The manufacturers therefore found it extremely difficult
to meet the brief summary requirement in a short television (TV) or radio advertisement.
At the same time, the body of the advertisement must give "fair balance" to the benefit and
risk information. That is, claims of drug benefits, such as safety and effectiveness, must be
balanced with relevant disclosures of risks and limitations of efficacy. An advertisement
was deemed to violation of section 502(n) if it was false, misleading or lacked “fair
balance”. (FDA, 1999)
In August 1997, the FDA reviewed its policies on broadcast advertisement and
issued “draft guidance” to manufacturers. (Rosenthal, 2002) In this new guidance, “brief
summary” can be replaced by "adequate provision” which is permitted by the FDA for
“dissemination of the approved or permitted package labeling in connection with the
broadcast presentation.” ((21 CFR 202.1(e)(1)) In details, the radio or TV advertisements
may meet the adequate provision requirement through an approach that will allow most of
a potentially diverse audience to have reasonably convenient access to the advertised
product's approved labeling. The approach must include the following components: a toll
free phone number, a print reference to DTC advertising, an Internet address, and a
statement that directs consumers to physicians or pharmacists for further information.
(FDA, 1999) However, advertisements broadcast through media such as television, radio,
or telephone communications systems must disclose the product's major risks in either the
audio or audio and visual parts of the presentation. (FDA, 1999) Without the need to
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include detailed risk information that accompanies magazine and other print
advertisements, TV and radio quickly become popular promotional tools in pharmaceutical
marketing.

More drugs suitable for DTC advertising
The U.S. health system has changed from primarily treating acute conditions to
treating more conditions that are chronic. (Williams et al., 1999) Many chronic diseases are
associated with age and are not curable. Drugs treating these diseases usually are
repeatedly used over a lifetime. Some chronic conditions such as hair loss, erectile
dysfunction (ER), and obesity lacked effective drug treatments before the late 1990s. Some
physicians also called them “lifestyle” diseases or "non-diseases". (Joel, 2001; Smith,
2002) Since the late 1990s, the pharmaceutical industry has introduced a number of new
drugs treating these diseases. Viagra for ER, Propecia for baldness, and Meridia for
weight-loss were good examples. These “lifestyle” drugs became very popular in the
market as consumers became more concerned with better quality of life in their healthcare.
Furthermore, other new prescription drugs emerged in the market that possessed milder
side effects or easier dosing forms than the comparable older drugs (NIHCM, 2002).
However, these products had neither cost advantages nor therapeutic advances over
existing therapies. These new drugs and the ‘life-style” drugs usually are not covered by
managed care plans (Hunt, 1998). DTC advertising provides a way to stimulate demand for
these products
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Intensified demand for health care information
Since the 1990s, many patients have expressed desire and interest in active
participation in their own healthcare. (Knapp, 2000) One of the important reasons was the
decline of trust in physicians. (Hunt, 1998) Consumers gradually became aware of
managed care mechanisms, such as restricted formularies and financial risk sharing by
physicians, and this awareness has tended to undermine their faith in physicians as agents
acting in their best interests. It led patients to seek outside information on drug therapeutic
alternatives, such as DTC advertisement. (Hunt, 1998)

The benefits and risks of DTC advertising
As a drug has benefits and risks, DTC advertising not only has its benefits, but also
raises concerns about misleading information. This results from the ethical dilemma of
marketers who sponsor DTC advertising: as health product providers, pharmaceutical
manufacturers are responsible for the optimal use of medications, however, as business
units, making maximum profit and surviving in the market is their goal. This conflicts of
interest may lead to biased information in DTC advertisements. (Mello et al., 2003;
Mintzes et al., 2002) At the same time, if a drug has little therapeutic advantage over other
products in the same class of drugs, and has an inflated price as a result of heavy DTC
advertisements, the practice would lead to waste in healthcare resources. In some extreme
cases, when the drug may potentially cause long-term risks to patients, the impact would
be even worse. For example, in December 2004, Merck had to announce a voluntary
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withdrawal of vioxx from the market because the FDA reported that patients taking Vioxx
chronically face twice the risk of severe cardiovascular events compared to patients
receiving a placebo. (FDA, 2004) Ironically, this drug has been one of the most advertised
brands through DTC advertising since its successful launch in 1999. In 2000 alone, Merck
spent over $160 million on media advertising for Vioxx. (Kaiser, 2001)
Therefore, with deeply planted conflicts of interest, DTC advertising and its impact
on public health is like a double-edged sword with negative side and positive side. Deeper
discussion about the two sides is necessary for a better understanding of influence of DTC
advertising on patients’ health behaviors.

Benefits of DTC advertising
Increase in awareness of under-diagnosed and untreated diseases
The FDA and the government agencies are concerned with untreated and undertreated disease among the population. The National Institute of Health (NIH) guidelines
stated that for every 100 patients who should be treated with drug therapy for high
cholesterol, currently only 25 patients are under treatment. (NIH, 2001) The Centers for
Disease Control and Prevention (CDC) also reported that 25% of all working-age people
with high blood pressure did not even know they have it. (CDC, 2001) As a result of these
concerns, the FDA (FDA, 2002) expected DTC advertising to help educate patients to
some extent and make them recognize the symptoms and harms of diseases.
Surveys have shown DTC advertising does alert consumers to the existence of
diseases and leads patients to search for more information. (FDA, 1999 & 2002; NCL,
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1998; Prevention, 1998, 1999 & 2001; Kaiser, 2001) Among surveyed consumers, 67%
agreed that advertisements increased their knowledge about disease. (NCL, 1998)
However, to what extent patients gained knowledge from advertisements was still in
question. Kaiser found that after seeing an advertisement, 70% of survey consumers knew
little or nothing more about the health condition for which the drug was indicated. (Kaiser,
2001) Some patients, therefore, sought more sources of drug information after seeing drug
advertisements. FDA surveys revealed that 43% to 53% of patients searched for further
information through such sources as the Internet, newspapers, and friends. (FDA, 1999 &
2002)

Increase in awareness of drug treatment
A number of surveys (FDA, 1999, 2002; NCL, 1998; Prevention, 1998, 1999 &
2001; Kaiser, 2001) indicated that DTC advertising enhances treatment awareness. This is
understandable since the basic function of DTC advertising is to offer education on
prescription drugs. With DTC advertisements, patients have more chances to know
available treatments for their diseases and to be prompted to discuss the new treatments
with their physicians. It potentially increases patients’ accessibility to therapeutic
alternatives. Roth (Roth, 1996) classified DTC advertisements’ contribution to treatment
awareness into five categories. The first one was new therapies used to treat conditions that
were formerly untreatable or poorly treated, such as erectile dysfunction or Alzheimer’s
disease. The second was drugs for conditions that tend to be under-diagnosed and undertreated, even though drug therapies were available, for example, hypertension or high-
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cholesterol. The third category was drugs that lower risks or have milder side effects, and
so expand the number of patients who can tolerate drug treatment. The fourth was brand
products that have cheaper, generic or over-the-counter (OTC) equivalents. The last
category is products with little benefit but that are safe and easy for physicians to prescribe.
According to this study, DTC advertisements for the first three categories offer patients
better therapeutic options. Advertisements for the last two lead to higher drug costs.

Enhance patients’ involvement in their own healthcare
Major national surveys also indicate that about one fourth of patients were
prompted by DTC advertisements to discuss with their physicians advertised treatments
that were related to their health. (FDA, 1999, 2002; Prevention, 1998, 1999 & 2001; NCL,
2002; Kaiser, 2001) Most patients (74% to 76%) agreed that DTC advertisements allowed
them to be more involved in their health care. (Prevention, 1998 & 1999) The involvement
includes searching for related health information; increased physician visits, better
discussion with physician about health conditions or new treatments, and improved
compliance with the advertised medication. Physicians felt comfortable about patients
playing an active role in their healthcare, and they would like to see this involvement.
(FDA, 2002) Patients’ compliance to medications also showed some improvement as a
result of DTC advertising. In the Prevention study, approximately one-fourth of the
respondents reported that DTC advertisements reminded them to refill their prescriptions
(Prevention, 2001). A FDA study reported a lower rate, 10%. (FDA, 1999) A case-control
study by Pfizer also indicated that patients who took the advertised drugs that they
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requested from physicians are significantly more likely to refill their prescriptions than
those who did not initiate a request. (Pfizer, 2001)

Concerns about DTC advertising
Misleading or deceptive information
According to 21 CFR.202.1 (FDA), misleading or deceptive information in DTC
advertising includes 1) misrepresenting or falsely reporting data, 2) declaring superiority
without scientific data to support the claim, 3) suggesting the drug is better than another
before it is proven, and 4) representing "off-label" use (new indications that are not
approved by the FDA). (FDA, 2004)
However,

pharmaceutical

manufacturers

continue

to

deliver

misleading

information to consumers in DTC advertisements. Between August 1997 and August 2002,
the FDA issued 88 regulatory letters and four warning letters for DTC advertisements that
violated its regulations. Among the letters, there were 14 letters to GlaxoSmithKline, six
letters to Schering Corporation, and five letters to Merck & Co. Inc., all about their
misleading advertisements. (GAO, 2002) It was reported that half of the regulatory letters
issued by the FDA in 2001 had cited advertisements that made misleading claims about a
drug’s efficacy. For example, in August 2001, the FDA sent a warning letter to the
distributors of Luxiq cream, a dermatological product, for falsely reported data. Its
advertisement claimed that the product was “highly effective for three out of four patients”,
even though the clinical study cited in the labeling had found that the cream improved
various symptoms for 41% to 67% of patients, or no more than two in three. (GAO, 2002)
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Unbalanced information on benefit and risk
Researchers have indicated that many advertisements tend to allot more space to
the positive features or drug benefits, while minimizing information about risk and adverse
effects (Mello, 2003; Mintzes et al., 2002). The FDA’s Division of Drug Marketing,
Advertising and Communication (DDMAC) raised complaints about the lack of risk
information in DTC advertisements (Smith, 1998). These complaints included: 1) lack of
reference to risks, adverse effects, and side effects; 2) not presenting risk information in a
prominent and readable manner; 3) using confusing language and technical terms that are
often misunderstood by the general public; 4) showing claims of safety not substantiated
by well-controlled studies; and 5) not providing balance between risk and efficacy, e.g.
small type for the risks and large type for efficacy. However, unbalanced information may
be inherent in advertisements, because the purpose of advertisements is to promote
products rather than to deter patients from using them.

Increase unnecessary physician visits and inappropriate drug prescribing
Some experts pointed out that brand-specific requests by patients may lead to
inappropriate drug prescribing because patients may not be able to correctly self-diagnosis
their disorders or symptoms. (Lexchin, 2002) In the opinions of researchers, patients
usually lack sufficient knowledge to self-diagnose. Therefore, it is unlikely that patients’
brand-specific requests are necessary or correct. Researchers also found that physicians are
more likely to become irritated from patient queries originating from DTC advertisements
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rather than other sources of information. (Zachry, et al, 2003) Surveys of physicians and
patients in primary care settings also showed a strong association between a physician’s
decision to prescribe and their perceptions of patient desire for a prescription even when
they know the drugs are not indicated. (Himmel et al., 1997; Schwartz, et al, 1989)
Therefore, if patients pressure physicians into prescribing the advertised drugs, the practice
may lead to inappropriate prescribing behavior. Interestingly, another study indicated that,
despite concerns about DTC advertisements’ negative consequences, there were no
differences in health effects between patients who took requested advertised drugs and
those who took other prescription drugs. (Weissman, 2003)

Increase in drug costs
Both the public and the pharmaceutical industry are highly concerned about costs.
From the public side, most brand-name drugs promoted in DTC advertisements have
higher prices than their therapeutic alternatives, especially their generic alternatives. If the
brand-name drugs were new therapies used to treat formerly untreatable or under-treated
conditions, or if they had lower risks or milder side effects, they would be better choices in
clinical practice. In this case, the advertised drugs’ higher prices would be acceptable. The
news drugs, regardless of the level of improvement, have cost industry billions of dollars
in research and development (R&D). Their R&D costs need to be recovered. This may
require spending even more money on promotion in hopes of gaining enough profit from
the market to support further research investments. The costs will be shifted to consumers
through inflated prices on drugs.

Driven by cost considerations, Managed Care
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Organizations (MCOs) have implemented new policies to limit the use of drugs with no
cost advantages or therapeutic advantages over existing therapies. This forced drug
companies to spend more money on DTC advertisements to promote these products.
(Hunt, 1998) As a result of heavy expenditures on marketing, it was reported that in 2000
the average price of advertised new drugs was nearly twice the average price of existing
drugs prescribed for the same indications. (Dana, 2003)

Return-on-investment (ROI) studies on DTC advertising
After investing billions of dollars in promotional expenditures, the pharmaceutical
industry has great concerns about the value and cost-effectiveness of DTC advertising.
Neslin’s return on investment (ROI) research indicated that, compared with other
marketing promotion tactics, such as detailing, drug sampling, and medical journal
advertisements, DTC advertising was not cost-effective. Neslin used a total of 391
marketed prescription drugs’ data provided by Scott-Levin and PERQ/HCL from 1995 to
1999. In the study, ROI was defined as the increase in revenue for each dollar invested in
DTC advertising. Neslin found that for each additional dollar spent on promotion, the ROI
was $1.72 for detailing, $5.00 for journal advertising, $3.56 for physician meetings and
events, but only $0.19 for DTC advertising. (Neslin, 2001)
Why was DTC advertising less effective? There are two potential answers. First,
DTC advertisements are not targeted. While DTC advertisements can focus promotion to
some extent, the percentage of the audience relevant for the content is still low. Second, the
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period of study 1995-1999 was probably a period of learning about DTC advertising.
Pharmaceutical companies were still investigating which types of advertisements were
most effective. In addition, the regulations allowing DTC advertisements on TV and radio
were not implemented until 1997.
A follow-up study conducted by Wittink looked at additional data through the year
2000. The outcome was still not favorable for DTC advertising. Compared with other
marketing tactics, DTC advertising had the lowest ROIs in every brand revenue category.
Many of the brands reported low or negative ROIs. The study also analyzed three
therapeutic categories: arthritis, asthma, and hypertension. Results showed DTC
advertising had the lowest ROIs (only $ 0.1) in each of the therapeutic classes as well.
(Wittink, 2002)
Kaiser’s study in 2003 suggested that DTC advertising had a positive ROI for five
therapeutic drug classes. (Kaiser, 2003) The five therapeutic classes were antidepressants,
cholesterol lowering, proton pump inhibitors, nasal sprays, and antihistamines. It was
reported that increases in DTC advertising were associated with significant growth in drug
sales. For every 10% increase in DTC advertising, total drug sales increased on average by
1%. Each additional dollar spent on DTC advertising in 2000 yielded $4.20 in additional
pharmaceutical sales that year for the 5 therapeutic drug classes.
In 2004, three years after Neslin’s study, IMS researchers conducted a new ROI
analysis. This study examined 49 brands between 1998 and 2003. DTC advertising’s carryover effect and lifetime value were considered in the new model. The carry-over effect was
a delayed response to DTC advertising. The concept of lifetime value was that once a
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patient filled a new prescription attributable to DTC advertising, all the patients’ refills
should be counted into the ROI of DTC advertising. IMS researchers found that when
averaged across the entire database, new prescriptions generated by DTC advertising only
accounted for about 20% of total DTC advertising contribution. Therefore, in most cases,
whether or not the carry-over effect and lifetime value were considered made the
difference between positive and negative ROIs. The IMS study also found that 90% of the
brands showed positive ROIs, 70% had over ROIs of over $1.5 ROI, and 35% had ROIs
of over $2.5 . (IMS, 2004)
Though DTC advertising showed better ROIs in recent years, the studies conducted
by Kaiser and IMS failed to compare DTC advertising’s ROI directly with other marketing
tools. Hence, there was no evidence that DTC advertising is more effective than the other
common forms of marketing promotion. The IMS study also indicated that brands with
sales below $200 million resulted in low or negative ROIs, which was consistent with
Neslin’s study ($0.59 ROIs for DTC advertising). At this sales level, detailing had a ROI
of

$3.70 and journal advertising had an ROI of $4.47. In other sales levels, DTC

advertising also showed lower ROIs. It showed that even when DTC advertising’s carryover effect and lifetime value were considered for study, DTC advertising was the least
effective among promotional tactics.
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Statement of Problem
Studies on ROI indicated that the outcomes of DTC advertising showed no
advantages over alternative promotional tactics. One of the most important reasons may be
that DTC advertisements were not efficiently targeted to consumers. (Neslin, 2001) From
pharmaceutical marketing prospective, further studies should examine the characteristics of
patients who were interested in the DTC advertisements, offering a basis to investigate the
types of patients who should be targeted with DTC advertisements.
Thus, the purpose of this study was to identify the types of patients who will visit
their physicians as a result of prescription drug advertisement. Two questions are
addressed in this study:
The first question is whether patients with different individual characteristics (such
as health status, gender, or race) are more likely to visit their physician as a result of seeing
a DTC advertisement for prescription drugs (DTC-prompted visits). The second question is
whether patients’ health beliefs about DTC advertising are associated with their DTCprompted visits. Individual characteristics in this study consist of four groups of factors,
including personal health status and healthcare utilization, demographics, socioeconomics,
and market factors. These factors will be explained in Chapter 3. In terms of the DTCprompted visits, there are three types of visit experience. The first one is the experience of
talking with physicians about a prescription drug for themselves. The second type is the
experience of talking with physician about a medical condition, illness or other health
concern of their own that patients had not discussed with physicians before. The third one
is the experience of talking with physicians about possible change in treatment for a
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medical condition or illness that patients already had. Once the factors that interact with
DTC advertising to influence patients’ physician visiting behavior are determined,
marketers can use the information to target consumer groups more efficiently.

Hypotheses
According to the two questions to be answered in this study, six hypotheses were
framed:

H1: There is a statistically significant relationship between patients’ individual
characteristics and whether or not they will talk with their physician about a prescription
drug after being prompted by a direct to consumer prescription drug advertisement.

H2: There is a statistically significant relationship between patients’ personal health
beliefs and whether or not they will talk with their physician about a prescription drug after
being prompted by a direct-to-consumer prescription drug advertisement

H3: There is a statistically significant relationship between patients’ individual
characteristics and whether or not they will talk with their physician about a new health
concern after being prompted by a direct-to-consumer prescription drug advertisement
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H4: There is a statistically significant relationship between patients’ personal health
beliefs and whether or not they will talk with their physician about a new health concern
after being prompted by a direct-to-consumer prescription drug advertisement

H5: There is a statistically significant relationship between patients’ individual
characteristics and whether or not they will talk with their physician about change in
treatment after being prompted by a direct-to-consumer prescription drug advertisement

H6: There is a statistically significant relationship between patients’ personal health
beliefs and whether or not they will talk with their physician about change in treatment
after being prompted by a direct-to-consumer prescription drug advertisement

Implications in practice
Findings from this study will help pharmaceutical marketers evaluate the influence
of DTC advertising on physician visits in different consumer groups. The major national
surveys have told us DTC advertising did influence consumers to some extent. These
surveys reported that 70% to 99% of consumers were aware of DTC advertisements. 18%
to 31% of consumers discussed advertised drugs with their physicians; and 6% to 9% of
consumers requested advertised drugs from their physicians. (FDA, 1999 & 2002; NCL,
1998; Prevention, 1998, 1999 & 2001; Kaiser, 2001) However, DTC advertising's
influence on physician visits among different patient groups, such as elderly patients,
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African-Americans, patients without prescription drug coverage and patients with different
health beliefs, were not examined in these national surveys. Several local studies covered
some of these issues based on their interests on patients’ attitude, value, and actual request
behaviors, but none of them has answered the questions with nationally generalizable
results.
Our study used nationally representative data to examine patients’ action in
response to DTC advertisements. Based on the findings, marketers could identify the
patients most likely to visit physicians as a result of DTC advertising, therefore, they could
target consumers more efficiently. The marketers can use the study outcomes to develop
customized messages and interactive tactics. Rather than the traditional media advertising
on TV or radio, which just delivers messages to the audience without targeting individual
differences, these customized messages and new technologies can make it easier to
stimulate demand according to the characteristics of each individual. For example, using
some direct response technologies on the Internet, marketers can send customized letters
and brochures to those most likely to switch to new treatments based on the answers that
respondents give to questions about their experience with a disease state or personal
beliefs. At the same time, emails could be sent to them to direct them to a web site with
information most relevant to their needs, such as the disease and new treatment knowledge.
This would be more effective than simply directing them to a home page where they have
to search for what they want. Therefore, as a result of more effective targeting based on
consumer differences, the industry could improve their return-on-investment ratio for DTC
advertising over time.
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CHPATER 2
LITERATURE REVIEW

The overview of the DTC advertising ROI studies told us that DTC advertising was
less effective than other marketing tools. One possible reason may be that DTC advertising
has not targeted patients efficiently. (Neslin, 2001) To solve this problem, further studies
need to examine those patients who are interested in the advertisements and identify those
who are most likely respond to DTC advertisements. So far, only a limited number of
studies have identified factors influencing patients’ attitude and behavior toward DTC
advertising.

Factors influencing patients’ attitudes toward DTC advertising
A study from University of Rochester has explored what kind of patients would
value the information provided by prescription drug advertisements using a Scott-Levin
data set. This study reported that consumers with children or chronic diseases value
prescription drug advertising more highly, while older consumers, recently sick patients,
and more educated consumers are more likely to value their physician’s opinions instead.
(Gonul et al., 2000)
A study by Doucette et al. looked at the effects of age and medication knowledge
on the public’s desire for additional drug information following DTC advertising exposure.
(Doucette et al., 1998) This was a mail survey with a random sample of 150 respondents.
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They found that older and less knowledgeable people were less likely to report a desire to
seek additional information, such as talking to a physician, after exposure to a DTC
advertisement. Among the information sources (i.e. physicians, pharmacists, a family
member or friends), physicians were the most strongly preferred for information on drug
benefit and risk. The knowledge levels in this study were reported by respondents only,
and may have been inaccurate.
Based on the results of a survey conducted by Prevention magazine, Sumpradit
explored consumers’ attitudes towards DTC advertising. (Sumpradit et al., 2002) The
study indicated that consumers who have ever asked their physicians for advertised
prescriptions tended to agree that DTC advertisements made prescription drugs appear
harmless and helped them make their own decisions on prescriptions.

Factors influencing consumers’ responses to DTC advertising
In 1999, the FDA carried out a survey on DTC advertising, as part of an evaluation
of the impact of the 1997 draft guidance on broadcast advertising. (FDA, 1999) In order to
improve the report’s accuracy, the study included 960 (90%) people who had seen their
physician within the past three months and 121 (10%) people who had seen their physician
more than 3 months previously. The FDA found a significant difference in response to
advertising between the two groups. Only 8% in the former group reported bringing up a
new health condition because of advertising, versus 27% for the later group (p < 0.001).
Each group had the same proportion of people covered by health insurance. Those who had
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seen a physician recently reported greater awareness of DTC advertising and significantly
poorer health status than those who had not. This survey confirmed the results of other
major surveys indicating that most consumers report positive responses to DTC
advertising. However, except for heath care utilization (defined as a physician visit), the
study did not examine other factors relating to people’s responses to advertising.
Kaiser conducted a case controlled survey on DTC advertising in 2001. (Kaiser,
2001) Researchers used a new, internet-based survey technology to show respondents
(viewer group) a particular drug advertisement and then asked them questions related to
the advertisement. They also included a “non-viewer” group of respondents who did not
view an advertisement and asked them similar questions. There were a total of 1,872
viewers and 639 non-viewers. Those with the greatest health needs, the elderly, and those
who reported that they are in fair or poor health were found to be more likely to report that
they talked to their physician about advertised drugs, though not more likely to receive a
prescription for the advertised drugs. For example, 39% of those aged 65 or older and 41%
of those with fair or poor health reported the experience of talking with a physician about
advertised drugs as a result of seeing a drug advertisement (compared to 30% of the
sample overall). In response to specific advertisements showed to them, those who have a
relevant medical condition were more likely to anticipate that they would talk to their
physician about the medicine. Significance levels on the differences were not stated in the
results.
Sumpradit also explored how consumers’ characteristics interacted with DTC
advertising to influence patient behaviors, such as asking for advertised prescriptions. This
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study used a subset of 1,102 consumers who responded to a 1998 national survey
conducted by Prevention magazine The findings indicated that consumers with chronic
conditions and positive attitudes toward DTC advertising were more likely to have the
experience of talking with physicians about the advertised drugs. (Sumpradit et al., 2002)
Peyrot et al. examined the effects of demographic factors, media exposure, attitude
and prescription drug knowledge on requests for advertised drugs. (Peyrot et al., 1998)
They carried out a random digit dialed (RDD) survey of 440 residents in Baltimore. The
study showed that the belief that drug advertising reduces prices, preference for generic
drugs, media exposure and drug advertising awareness were positively associated with
drug requests, but the belief that physicians should be the sole source of drug information
was negatively associated with the probability of request. The authors described the effects
of different media exposure (i.e. print media exposure, television exposure) on patients’
responses to drug advertising, but in the published article, they did not clearly explain the
concept of media exposure. Measurements for media exposure were also not described in
detail by the authors. Rather than measuring the amount of awareness, this study simply
measured drug advertising awareness with “whether awareness exists”, that is, respondents
were asked whether they were aware of drug advertising or not. It was also one of the
limitations pointed out by authors that “more comprehensive and in-depth measures of
drug advertising awareness” should be developed. (Peyrot et al., 1998)

Univariate

analyses found that women were more likely to request an advertised drug than men;
whites than non-nonwhites; and professionals and better educated than those with less
education. However, when the model was adjusted for attitudes and media exposure, no
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statistically significant differences were found for race, gender and education. No
relationship was found between age and requests for advertised drugs. The research did not
include information on insurance coverage and health care utilization. The time of the
study was in 1990, well before the changes to FDA regulations on DTC advertising in
1997. Exposure to DTC advertising was therefore much lower than it would currently be.
All survey respondents were residents of central Baltimore. This limits the generalizability
of the study.
In a survey of primary care physicians in Sacramento, California, and Vancouver,
British Columbia, researchers analyzed the association between advertising exposure and
patients’ requests for advertised drugs. (Mintzes et al., 2003) A total of 78 physicians
(Sacramento n = 38, Vancouver n = 40) and 1431 adult patients (Sacramento n = 683,
Vancouver n = 748) were selected for study. Physicians were requested to complete a
questionnaire about a patient immediately following the patient visits. In this research, they
measured advertising exposure as the number of listed drugs a person had seen advertised.
Researchers found patients with higher exposure to DTC advertising, patients who had
conditions that were potentially treatable by advertised drugs, and those with greater
reliance on advertising requested more advertised drugs. They used models controlling
self-reported health status, use of healthcare service, health information source, age, sex,
household income, and drug insurance coverage. Information on the significance of these
factors was not reported in the study. This research was limited in that only respondents
from two cities were surveyed, and one of the cities was in Canada where the healthcare
system is substantially different from the U.S. healthcare system.
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Summary of literature
A review of the literature showed that several factors have an impact on patients’
attitudes towards DTC advertising. Specifically, patients with children, chronic disease
conditions (Gonul et al., 2000), less knowledge (Doucette et al., 1998), or former
experience of asking for advertised drugs have positive attitudes towards DTC advertising
(Sumpradit et al., 2002). While older, recently sick patients, or more educated consumers
preferred physicians’ opinions rather than drug advertisements as sources of drug
information (Gonul et al., 2000).
Studies also indicated that some factors can influence patient’s behavior of asking
for advertised drugs. Multiple factors were found positively associated with drug request
prompted by DTC advertising: the belief that drug advertising reduced prices, preference
for generics, media exposure (including DTC advertisements), drug advertising awareness,
conditions potentially treatable by advertised drugs, and reliance on advertisements.
(Peyrot et al., 1998; Mintzes et al., 2003). Patients who have seen their physicians recently
(FDA, 1999), patients with the greatest health needs, elderly patients, those in fair or poor
health (Kaiser, 2001), those with chronic conditions and positive attitudes toward DTC
advertising (Sumpradit et al., 2002) were more likely to talk to their physicians about
advertised drugs.
Although there were a number of national surveys, most of them were descriptive
studies, and did not statistically analyze the relationship between patients’ response to
DTC advertising and factors, such as demographics, health status, and exposure to
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advertising, which may potentially influence patient’s behavior. Several studies conducted
in more limited geographic areas examined the factors influencing patients’ attitudes or
behaviors in response to DTC advertising. Because of limitations in sample size, location,
or differences in nationality and healthcare system, few of them were generalizable to
larger populations in America. Several studies have explored one type of physician visit,
like talking to physician about advertised drug or request for advertised drugs directly,
however, no single study has looked at the factors associated with different types of DTCprompted visits.
To enhance the understanding of DTC advertising’s influence on human health
behavior, our research examined three types of DTC-prompted visits. The first type of visit
was talking with physicians about a prescription drug for themselves. The second type was
talking with physicians about a new medical condition. The third one was talking with
physicians about switch to new treatment. Examining all three types of visits constructed a
more complete picture of the effects of DTC advertising on patient’s interactions with their
physicians. Furthermore, our study of factors that are associated with patient’s DTCprompted visits were based on nationally representative data.

Conceptual framework
We developed a conceptual framework to explore how patients’ characteristics
interact with DTC advertising to influence their physician visits. There is little theoretical
guidance in the literature with respect to the structure of a model predicting patients’ DTC-
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prompted visits. However, the problem is not complex if we build the conceptual
framework based on related theories and literature. The major constructs for our
conceptual model were selected from two behavioral theories.

The Theory of Reasoned Action
The Theory of Reasoned Action, as a general theory of human behavior, was
introduced by Fishbein and was further developed and tested by Fishbein and Ajzen.
(Fishbein et al., 1980) The theory attempts to explain the relationship among beliefs,
attitudes, intentions and behavior. It is based on the assumption that human beings are
usually quite rational and their behaviors are under volitional control. The theory views a
person's intent to perform or to not perform a behavior as the intermediate determinant of
the action. Individuals will intend to perform a behavior when they are motivated by their
attitude and subjective norms. (Fishbein et al., 1980) That is, the behavior is more likely to
be performed when they have positive attitude about the behavior and when they have
positive normative belief, believing that important others (referents) think they should
perform it. Instead of predicting patients’ intention to visit a physician as a result of DTC
advertising, we used attitude and subjective norms to predict their behavior directly.
The Theory of Reasoned Action has been applied extensively in the health field to
predict several health behaviors, such as smoking and exercise. (Kaplan et al., 1993)
Recently, some mass media campaigns have successfully applied the theory in health
promotion. (Randolph et al., 2004) These campaigns tried to focus marketing efforts on the
factors and determinants that could potentially change consumer’s health behavior. For
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instance, norms about alcohol consumption were successfully changed by a campaign to
discourage binge drinking on college campuses. (Thombs et al., 2002) Oh and his
colleagues also based their campaigns on the Theory of Reasoned Action to promote
awareness of risks and screening for chlamydia, and proved to be successful. (Oh et al.,
2002)
In this study, we attempted to apply the Theory of Reasoned Action to patient’s
DTC-prompted visits. When patients visit their physicians as a result of DTC advertisings,
they are assumed to be under volitional control rather than being controlled by emotions.
There are several potential reasons. First, patients are usually serious about their diseases
and treatments. (Hunt, 1998) Second, they value the recommendations from the sources
(referents) that they usually receive healthcare information from, such as physicians,
friends or TV advertisements; (Gonul et al., 2000) Third, when they initiate a discussion or
request for advertised drugs during the visits, patients usually have knowledge about the
disease and the new treatment. (FDA, 2002) A physician survey on DTC advertising has
reported that when a patient asks about a drug, 88% of the time they had the condition that
the drug treated, and 80% of physicians believed patients understood what condition the
drug treats. (FDA, 2002) Therefore, the Theory of Reasoned Action can be applied to
predict patient’s DTC-prompted visit.
Since the database used in this study lacked information on patients’ attitudes
toward DTC advertising, subjective norm was the only variable adopted from the Theory
of Reasoned Action. According to the theory, the potential referents or sources for
healthcare information could be family and friends, pharmacists, physicians, television or
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radio, and advertisements on TV and other media. We tested the relationship between
patient’s behavior of being prompted to visit their physician and using advertising
information as their subjective norms. For example, if DTC advertisement is a patient’s
most important information resource for healthcare, then he or she should be more likely to
talk to their physician about advertised drugs and request switches to new treatments.

The Health Belief Model (HBM)
The Health Belief Model was developed in the 1950s to explain and predict
individuals’ inaction or noncompliance to a certain interventional behavior. (Rosenstock,
1988) It was the oldest and most widely used model specifically developed to explain
health behavior. (Kaplan et al., 1993) The HBM proposes that behavior depends on how
much a person values a particular goal and on his or her judgment that a particular action
will achieve that goal. If the goal is to avoid a health problem, the person must feel
vulnerable (perceived susceptibility) to a problem perceived to be potentially serious
(perceived severity), and he or she must estimate that specific action will be beneficial in
reducing the health threat (perceived benefit) and will not involve overcoming obstacles
(perceived barriers). (Champion, 1984) Therefore, the model includes four principal
components: perceived susceptibility, perceived severity, perceived barriers and perceived
benefits. (Rosenstock, 1988) The theory has been applied to several areas of healthcare
including preventive health behavior, adherence to medical regimens, sick-role behavior,
and health promotion behavior. (Kaplan et al., 1993)
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From pharmaceutical marketing’s point of view, the goal of DTC advertising is to
educate patients about the existence and severity of diseases, make them understand the
benefit of advertised treatments, and finally prompt them to ask the physician to prescribe
the advertised drugs. DTC advertising therefore could be looked on as an educational
intervention for promoting patients to visit physicians.Limitations of the two theories

Limitations on the Two Theories
The Theory of Reasoned Action and Health Belief Model both are psychosocial
models. They account for only as much of the variance in health behaviors as can be
explained by attitudes and beliefs that are obvious to and consciously evaluated by
individuals. (Ogden, 2003) Other factors related to the individual, such as demographic
variables, health status and health utilization factors, socioeconomic factors, and market
factors, may play a role in influencing behavior, but they are not included in the two
models. It is the case that due to outside factors a person may not be able to perform a
behavior despite a strong desire to do so.
To address this gap, our study also incorporated external factors, including personal
health status, demographics, socioeconomics and market influence into the models to test
their influence on the outcomes. The conceptual framework of the relationship between
explanatory factors, intervention, and outcomes can be drawn as a flow chart. (See Figure
2.)

39

CHAPTER 3
METHODS
In this chapter, we will describe the source of data used in the study, define the
variables in operational terms, and discuss statistical procedures that were employed for
the analysis. In chapter 2, based on the Theory of Reasoned Action and the Health Belief
Model, we constructed a conceptual framework consisting of outcomes, intervention and
five groups of explanatory factors. The outcomes included talking to a physician about a
prescription drug, talking to a physician about a new health condition, and talking to a
physician about a possible change in treatment. The intervention was whether a patient had
ever seen or heard an advertisement for a prescription drug in the past 12 months. The
explanatory factors were personal beliefs, socioeconomics, demographics, health status,
and market factors. Chapter 3 will operationalize the conceptual framework for predicting
or explaining patients’ physician visit experiences as a result of DTC advertisements.

Data source
This study used data from a national survey, “Public Health Impact of Direct-toConsumer Advertising of Prescription Drugs, July 2001- January 2002: [United States]”
(Weissman, 2003). The data set was available from the website of Inter-university
Consortium for Political and Social Research (ICPSR). A detailed description of the survey
design and procedure can be found at the ICPSR website. A team of researchers from
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Harvard Medical School and Harris Interactive designed the survey. Professionals from
Harris Interactive collected the data. A 20-minute telephone interview was conducted with
a nationally representative sample of 3000 adults between July 5, 2001 and January 16,
2002 (Weissman, 2003). The unit of analysis was adults aged 18 and older living in the
continental United States and having telephones. The questionnaire included 179 questions
focusing on five categories:
The first category was health status and utilization. Respondents were asked about
their overall health, the estimated time since their last physician visit, whether they were
currently taking any prescription drugs, from what sources and how often they received
medical information, and which health information resource was most important to the
respondents.
The second category was experience with DTC advertising, including questions on
the media in which they had seen drug advertisements, whether their friends had
mentioned advertisements to them, and whether the advertisements had provided useful
information.
The third category was visits to physicians to discuss information. Respondents
were questioned on whether advertisements had ever prompted them to talk to their
physicians about a prescription drug, a new health condition, or a possible change in
treatment for an ongoing concern.
The fourth category was outcomes of visit, such as whether the drug prescribed by
their physician was the same drug they had seen in advertisement, did they fill or take the
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prescription that their physician prescribed, and their satisfaction with the drug’s
performance if they filled the prescription.
The last category included background information: gender, age, race, marital status,
insurance coverage for prescription drugs, education, employment status, and income.

Sample design
The sample was selected through computerized random digit dialing (RDD). RDD
ensured that the sample included not only those persons whose telephone numbers were
listed in telephone directories but also those whose numbers were not listed (Weissman,
2003). The researchers used a stratified sampling process. This sample design based the
number of persons in each stratum of the sample on the proportion of the stratum in the
total population (Babbie, 1990). It ensured proper representation of enrollees in different
regions of America. The adjusted response rate was 58 percent. The survey data were
weighted by age, race, education, health insurance status (insured or uninsured), household
size and gender to reflect the demographic composition of U.S. population. This sample
was demographically similar to the U.S. population as described in the March 2001
Current Population Survey from the U.S. Census Bureau (Weissman, 2003).
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Survey Procedures
A computer-assisted telephone interviewing system (CATI) was used for on-line
data entry and editing of telephone interviews. The interview process was flexible. It
varied depending on whether a respondent had seen or heard a DTC advertisement, talked
to a physician about information presented in a DTC advertisement, and based on the
outcomes of the discussion (receiving a prescription, filling the prescription and taking the
drug as prescribed). For example, if a participant had not seen any advertisements or been
told about an advertisement by a friend or a relative, no question was asked about
physician visits or visit outcomes. Instead, CATI would skip to the next relevant question
(Weissman, 2003). A number of methods were used to maximize the response rate. A $10
incentive was offered for completion of the interview. Two dollars were mailed to
nonrespondents as an additional incentive.

Nonrespondents were also sent a letter

explaining the purpose of the survey and encouraging them to participate. Attempts were
made to contact nonrespondents at various times of the day and days of the week.
Researchers also set up a toll-free number that respondents could call to complete the
survey at a convenient time (Weissman, 2003).

Variables in conceptual framework
Dependent variables
The conceptual framework specified three outcome variables as a result of DTC
advertising: visit for prescription drug, visit for new condition, and visit for treatment
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change. Only those who had seen or heard an advertisement for a prescription drug in the
past 12 months were asked about their physician visits. Rather than using a single
dependent variable, we used three dependent variables to measure DTC-prompted visits.
One of the advantages was that it offered a comprehensive overview of physician visits for
different purposes. Another advantage was that it helped identify the strongest predictors
of DTC-prompted visits. For instance, if a factor or an independent variable was found to
be related to all three dependent variables, it was probably a strong predictor of DTCprompted visit. In contrast, if a factor or an independent variable only showed significant
association with one dependent variable, it was probably a weaker predictor than the
former one.

Visit for prescription drug:
Visit for prescription drug was defined as whether an advertisement for a
prescription drug ever prompted the respondent to talk to a physician about a prescription
drug for themselves. If the person responded “yes”, the variable “visit for prescription drug
” was given a value of one. If the answer was “no”, then the variable was given a value of
zero.

Visit for new condition:
Visit for new condition was defined as whether an advertisement for a prescription
drug ever prompted a respondent to talk to a physician about a medical condition, illness,
or other health concern of their own that they had not discussed with a physician before. If
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the person responded “yes”, the variable “visit for new condition” was given a value of
one. If the answer was “no”, then it was given a value of zero.

Visit for treatment change:
Visit for treat change was defined as whether an advertisement for a prescription
drug ever prompted the respondent to talk to a physician about a possible change in
treatment for a medical condition or illness that he or she already had. If the person
responded “yes”, the variable “visit for treatment change” was given a value of one. If the
answer was “no”, then it was given a value of zero.

Independent variables
The independent variables were grouped into five factors: personal beliefs,
demographics, socioeconomics, health status, and market factors.

Personal beliefs
The personal beliefs consisted of variables identified from the two behavioral
theories. Variables from four subgroups were included in the personal belief factor. They
were subjective norm (two variables: source importance and source utilization), perceived
benefit (two variables: awareness of treatments and patient-physician communication),
perceived barrier (two variables: unbalanced information in DTC advertisements and
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physician’s authority), and perceived severity (self-reported overall health). The following
questions were used to measure respondents’ personal beliefs.

Subjective norm
Source utilization: “How often do you get information about health from?”
(TV/radio, internet, newspapers or magazines, family and friends, a pharmacist, pamphlets
in a physician’s office, or a physician) (Weissman, 2003)
Respondents were asked about their utilization of each source of information:
television or radio (not including advertisements), Internet websites, newspapers or
magazines (not including advertisements), family and friends, a pharmacist, pamphlets in a
physician’s office or waiting room, and physicians. Responses for the utilization of each
source were measured with: 1 = never, 2 = hardly ever, 3 = sometimes, and 4 = often.
Referent source: “Which one of the sources was the most important in prompting you to
talk to your physician?” (Weissman, 2003)
For this question, we classified the above sources/referents into two categories:
media source or non-media source. Media sources included television or radio, Internet
websites, newspaper or magazine, pamphlets and advertisements for prescription drug.
The remaining sources were defined as non-media sources. If a person chose a media
source, the variable “referent source” was given a value of one. If the choice was nonmedia source, then variable was given a value of zero.

Perceived benefit
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Awareness of treatments: “(DTC advertisements) made me aware of a treatment or
of treatments that I did not know about.” (Weissman, 2003)
Patient-physician communication: “(DTC advertisements) helped me to have better
discussions about my health with a health professional.” (Weissman, 2003)
Responses to both questions were measured with 4-point likert scales: 1= strongly
disagree, 2= agree, 3= disagree, 4 = strongly disagree.

Perceived barrier
Unbalanced information: “(DTC advertisements) did not provide information on
risks and benefits in a balanced manner.” (Weissman, 2003)
Physician’s authority: “(DTC advertisements) made me less confident in my
physician’s judgment.” (Weissman, 2003)
The answers to questions about unbalanced information and physician’s authority
were also measured with 4-point likert scales: 1= strongly disagree, 2= agree, 3= disagree,
4 = strongly disagree.

Perceived severity
“Overall health: overall, how would you describe your health?” (Weissman, 2003)
Five categories were used to measure overall health: 1 = poor, 2 = fair, 3 = good,
4 = very good, and 5 = excellent. The literature indicated that those who reported they
were in fair or poor health were more likely to talk to their physician about advertised
drugs, though not more likely to receive a prescription for the medicine (Kaiser, 2001).
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Socioeconomic factors
The socioeconomic factors included education, income and prescription insurance
coverage.

Education:
Five levels were used to measure education: less than high school graduate (coded
1), high school graduate or equivalent (coded 2), completed some college, but no degree
(coded 3), college graduate (code 4), graduate school level and above (coded 5). Education
has been identified as an important factor to predict patients’ attitude toward DTC
advertising. According to Gonul, educated consumers were less likely to trust prescription
drug advertisements (Gonul, 2000). We assumed education level has an impact on DTCprompted visits.

Income:
Income was coded as: 1 = income less than $15000, 2 = income above or equal to
$15000 and less than $30000, 3 = income above or equal to $30000 and less than $75000,
and 4 = income above or equal to $75000. There was no literature indicating that income
has an impact on patient’s experience of talking with a physician about advertised
prescription drugs. However, studies have reported that income plays an important role in
the patient’s medical decision making. For instance, higher income groups were more
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likely to use prescription drugs for their conditions as compared to lower income groups
(Stuart, 1998); and for Medicaid beneficiaries, even small increases in co-pay for
“essential” medications could have substantial unintended effects, such as sharp increases
in ER visits and outpatient visits because of non-compliance (Soumerai, 1994).

Prescription insurance coverage:
Prescription coverage was coded as: 1 = all prescription expenditures are covered
by insurance, 2 = some prescription expenditures are covered by insurance, and 3 = no
prescription expenditures are covered by insurance. Advertised prescription drugs were
usually more expensive than non-advertised drugs (Kaiser, 2001). Patients had to pay more
out of pocket for advertised drugs if they did not have our only had limited prescription
drug coverage, which might deter them from visiting their physicians to discuss an
advertised prescription drug. A former study has shown that restriction in prescription
drug coverage has a significant impact on prescription decisions among vulnerable
populations (Soumerai, 1994). We did not include insurance coverage as a predictive
variable because normally when a patient has prescription drug coverage they also have
coverage for hospital and medical expenses.

Putting both insurance variables in a

regression model might introduce multicollinearity (Field, 2003).
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Health status factors
Health status factors consist of disease conditions, medication use, and healthcare
service utilization.

Disease conditions:
In this study, we attempted to explore how different disease conditions interacted
with DTC advertising to influence patients’ physician visit behavior. Seven chronic
conditions were included in the survey and considered for analysis: diabetes, arthritis,
allergy, high cholesterol, depression, asthma and anxiety. For each chronic condition,
respondents were asked whether a physician or another health professional had told them
that they had the condition. If they responded “yes”, the variable for that disease condition
was given a value of one. If the answer was “no”, then that variable was given a value of
zero.
No study has investigated how having a particular disease condition would affect
one's likelihood of visiting a physician for an advertised drug. We chose the seven chronic
disease conditions for study because drugs treating these conditions have been heavily
advertised over the years. Examples included Lipitor for high cholesterol, Zoloft for
depression, Claritin for allergy, and Vioxx for arthritis.

Medication use
Medication use was defined by whether or not respondents were taking any
prescription drugs on a regular basis. If they responded “yes”, the variable “medication
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use” was given a value of one. If the answer was “no”, then the variable was given a value
of zero. We assumed that patients who were on their medications on a regular basis were
normally concerned with their treatments and visited their physician regularly and,
therefore, had more chance to ask their physicians about advertised prescription drugs.

Healthcare service utilization
Healthcare service utilization was assessed as the frequency of physician visits.
Participants were asked how long it had been since the last time they visited a physician
for non-emergency purposes. The responses to this question included: within the last three
months (coded 1), more than three months but less than one year ago (coded 2), and more
than one year ago (coded 3). We supposed that patients who use healthcare services
frequently have more chances to talk with their physicians about DTC advertisements than
those who seldom visit a physician. They thereby were assumed to be more likely to visit
their physician for an advertised prescription drug.

Market factors
Market factors were marketing influences on patients when they were exposed to
advertisements in mass media campaigns for prescription drugs. Market factors consisted
of advertisement attentiveness and advertisement information utilization.

Advertisement attentiveness:
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Advertisement attentiveness was defined as patient’s attentiveness to DTC
advertisements. Since the survey did not include a direct measure of advertising
attentiveness, we constructed a proxy variable for this measure. We assumed that those
patients having chronic conditions treatable with advertised drugs would be more attentive
to DTC advertisements for those drugs; healthy patients or those without the condition
would not be interested in the information. Minitz’s study has indicated that patients with
conditions potentially treatable by advertised drugs were more likely to request advertised
drugs (Minitz, 2003). We further assumed that patients’ advertisement attentiveness
increased with DTC spending on drugs treating their diseases. Thus, the proxy value of
“advertisement attentiveness” for each respondent was based on the DTC spending on the
drugs used to treat the respondent’s chronic conditions.
DTC spending data were available from National Institutes of Health Care Management
(NIHCM) annual DTC advertising report. According to the report, the top 50 most heavily
advertised drugs accounted for 95 percent of total DTC spending in 2000 (NIHCM, 2001).
The DTC spending on the top 50 drugs were classified into different therapeutic categories,
including anti-arthritis, anti-depressant, lipid lowering, anti-anxiety, anti-diabetes, and
other categories (NIHCM, 2001). Drugs for treating acute diseases were excluded from this
study because DTC spending on these drugs was less than 5%, the impact of which could
be neglected for this study (NIHCM, 2001).
For each of the seven chronic conditions (diabetes, arthritis, allergy, high
cholesterol, depression, asthma, and anxiety), we first coded each chronic condition for
each respondent as a dummy variable (0 = without this condition, 1 = with this condition)
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We then weighted the dummy variable with annual DTC spending on drugs treating this
chronic condition. In some cases, a respondent may have had more than one chronic
condition. For instance, if a respondent reported having three chronic diseases, the
estimated value of his or her “advertisement attentiveness” can be inferred from the sum of
DTC spending on drugs for the three diseases. The calculation formula was as follows:
f (x) = ∑ βk x (x = dummy, k = 1,2,…,7)
β = DTC spending on drugs for each chronic condition in 2000
We then used SPSS’s “categorize variables” function to convert continuous numeric data
to a discrete number of categories. After ranking cases in ascending order, data were
categorized based on percentile groups, with each group containing approximately the
same number of cases. In our study, a specification of four categories (1 = very low, 2 =
low, 3 = high, 4 = very high) would assign a value of 1 to cases below the 25th percentile,
2 to cases between the 26 th and 50th percentile, 3 to cases between the 51st and 75th
percentile, and 4 to cases above the 75th percentile. We used this new variable as a proxy
variable to estimate the patients’ attentiveness to DTC advertisements.

Advertisement information utilization
Advertisement information utilization was measured by asking how often patients
get information about health care from advertisements on TV and radio, in newspapers or
magazines. Responses were coded as: 1 = never, 2 = hardly ever, 3 = sometimes, and 4 =
often. We expected that advertisement information utilization was positively associated
with physician visits as a result of DTC advertising.
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Demographic factors
Demographic factors were another component of the conceptual framework
constructed in this study. They consisted of sex, age, race, and marital status.

Age
Age was self-reported by respondents during the survey. Studies showed that
patients’ responses to DTC advertisement varied with age (Doucette et al., 1998; Gonul et
al., 2000; Kaiser, 2001). Older consumers were less likely to report a desire to seek
additional information, such as talking to a physician after exposure to a DTC
advertisement. It was reported that older consumers were more likely to trust their
physician instead of advertisement (Gonul et al., 2000). We assigned respondents to three
age groups: 18 to 34 (coded 1), 35 to 64 (coded 2), 65 and older (coded 3).

Gender
Gender was coded one for male and zero for female. Pyrot found women were
more likely to request an advertised prescription drug than men were. However, when his
model adjusted for attitudes and exposure to DTC advertisements, no difference was found
between genders (Pyrot, 1998).

Race:
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In this study, race was coded one for white, two for black and three for other race.
A former study indicated that whites were more likely to request an advertised prescription
drug than nonwhites in the univariate analysis (Pyrot, 1998). When the model was adjusted
for attitudes and exposure to DTC advertisements, no difference was found among races.

Marital status
Marital status was coded as one for single respondents and as zero for non-single
respondents. Single respondents included divorced, separated, widowed, single and never
married. Non-single respondents included married and living with a partner.

Intervention
The intervention in this study was whether a patient had seen or heard an
advertisement for a prescription drug in the past 12 months. Respondents were required to
answer with “yes” or “no”. The interventional variable was not added to the regression
analysis because only those who had seen or heard an advertisement for a prescription
drugs in the past 12 months were asked about their physician visits.
The variables, including three dependent variables and all independent variables
used in this study were presented in Table 3.

55
Data analysis
Statistical analyses were performed with SPSS 11.5 for Windows (SPSS, 2002).
We first conducted descriptive analysis on the predictive and dependent variables to
understand each variable’s characteristics and distribution. We then conducted simple
bivariate logistic regression analysis to determine strength and direction of relationship
between each independent variable and the dependent variables. The independent variables
with a weak or without association with the dependent variables were excluded from the
logistic regression models to reduce multicollinearity and simplify the models. We also
examined the strength of association among independent variables to identify variables that
were highly correlated, so that we could take appropriate measures to address the problem
of muticollinearity.

Multicollinearity
Multicollinearity was an important issue that needed to be addressed because over
25 predictive variables were added to each regression model. Multicollinearity was a result
of strong correlation between independent variables. The existence of multicollinearity
may result in inflation of parameter (coefficient) estimates and consequently incorrect
conclusions about the relationship between independent and dependent variables (Field,
2003). Thus, we performed co-linearity diagnostics among the independent variables to
examine their tolerance and values of variance inflation factor (VIF). Tolerance values
ranged between zero and one and indicated how much variability of one independent
variable cannot be explained by other independent variables in the model. The variance
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inflation factor (VIF) was 1/Tolerance. It was the degree of inflation in the variances of the
parameter (coefficient) estimates due to multicollinearity among the independent variables.
There was no gold standard for the cutoff value when using VIF for determining the
presence of multicollinearity. In this study, values of VIF exceeding 10.0 were regarded as
indicating multicollinearity (Greene, 1997).

Multivariate analyses
Three multivariate logistic regression models were constructed to test the effects
of the predictive factors in our model on DTC-prompted visits. Just like linear regression,
logistic regression gives each regressor a coefficient or parameter estimator β

1

which

measures the regressor's independent contribution to variations in the dependent variable.
In a logistic regression, the dependent variable is a binary variable with values of 0 and 1.
The advantage of logistic regression is that it makes no assumptions about the distribution
of the independent variables. They do not have to be normally distributed or of equal
variance within each group (Lattin at el., 2003; Field, 2003). The relationship between the
predictor and response variables was not a linear function in logistic regression. Instead,
the logistic regression function was used, which was the logit transformation of θ:

An alternative form of the logistic regression equation is:
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In the above model, the logit transformation of θ on the left side of the function
stands for the logit transformation of dependent variable (visit for prescription drug, or
visit for new condition, or visit for treatment change). The variables x1 …. xk represent
each of the independent variables from five groups of factors. We included different
independent variables from five groups of factors (personal beliefs, demographic factors,
socioeconomic factors, health status factors and market factors) in each logistic regression
model. α is the constant of the equation. β1 … β i is the coefficient of each independent
variable. Our hypothesis was that β 1 = β 2 = β 3…= β i = 0, which assumed that there is
no statistically significant relationship between each independent variable and the
dependent variables (visit for prescription drug, or visit for new condition, or visit for
treatment change).
In the logistic regressions, Wald chi-square tests were conducted to test the
significance level of each regressor. Reference groups were used when the categorical
variables had more than two categories or levels. Usually the reference group is the lowest
level.
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CHAPTER 4
RESULTS

In Chapter 3, we discussed the data sources used for the study, operationalized the
dependent and independent variables, and described statistical procedures for analyses. In
this chapter, we will present the study results.

1. Descriptive analyses
The characteristics of respondents are presented in Table 5. Among the
respondents, 48% were females and 80% were white. Most respondents were between 35
and 64 years of age with annual income of $30,000 or more. Most were fully or somewhat
covered with prescription drug insurance (including Medicare or Medicaid), but 20% of
respondents had no prescription insurance coverage. This sample of 3000 respondents was
demographically similar to the U.S. population as described in the March 2001 Current
Population Survey from the U.S. Census Bureau (Weissman, 2003). The descriptive
analysis of dependent variables and the intervention are listed in Table 6. In the past 12
months, 86% of respondents had seen or heard an advertisement for prescription drugs.
Among the respondents, 27% had been prompted talk to a physician about a prescription
drug for themselves; 16% had been prompted to talk about a new health condition of their
own; 17% had been prompted to ask their physician about a possible change to new
treatment.
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2. Multicollinearity
We ran multicollinearity tests to examine the relationships between independent
variables. We wanted to find how much variability of one independent variable can be
explained by other independent variables in the model. If other independent variables can
explain most of the variance of an independent variable, there exits multicolinearity
between this independent variable and other ones. The existence of multicollinearity may
result in inflation of coefficient estimates in multivariate models, and consequently
incorrect conclusions about the relationship between the independent and dependent
variables (Field, 2003). One way to deal with multicollinearity is to exclude one of each
pair of highly correlated independent variables from the multivariate regression model
(Field, 2003) In this study, a value of the variance inflation factor (VIF) exceeding 10 was
regarded as an indication of multicollinearity (Greene, 1997; Field et al., 2000). Colinearity diagnostic tests showed that most independent variables’ VIF values were lower
than 3. (See Table 7.) The exception was “advertisement attentiveness” (VIF = 6.28). Its
VIF was higher than 3, but still lower than the cutoff value of 10. Since no apparent
multicollinearity was found among the independent variables, the parameter estimates
(coefficients) in the logistic regression models was unlikely to be inflated.

3. Outcomes on visit to discuss prescription drug
3.1. Bivariate analyses
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The purpose of the bivariate analysis was to identify the strength and direction of
the association between the dependent variable (“visit for prescription drug”) and
individual independent variables. If we found there was no or very weak association
between the dependent variable and an independent variable, the particular variable would
be excluded from the multivariate regression model in order to reduce multicollinearity and
simplify the models. We used a cutoff value of p = 0.25 (Hosmer et al., 2000). Since the
dependent variable and independent variables were categorical, we ran Pearson chi-square
tests to examine the relationship between the dependent variable and each independent
variable. Bivariate analyses showed that marital status was not associated with visit for
prescription drug (p = 0.85). Hence, marital status was excluded from the multivariate
analysis. All other independent variables were associated with visit for prescription drug.
The results of Pearson chi-square tests were shown in Table 8.

3.2 Mutivariate analysis
3.2.1. Model evaluation
Stepwise logistic regression was conducted to determine which independent
variables were predictors of visit for prescription drug. After running stepwise logistic
regression, only nine variables stayed in the model. The variables with significant effects
are listed in Table 9. Hosmer and Lemeshow’s Goodness-of-fit test statistic (Hosmer et
al., 2000) was much greater than 0.05 (p= 0.863). This suggested no significant difference
between the observed and model-predicted values of the dependent variable. Therefore, the
model’s estimates fitted the data at an acceptable level. Regression results indicated the
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overall model was statistically reliable in distinguishing between visit for prescription drug
and no visit for prescription drug. (-2 log Likelihood = 1888.73; Chi-square = 797.1, df =
19, p < 0.0001). The model correctly classified 93.8% of those in the “no visit” and 48.5%
of those in the “visit” category.

3.2.2 Model outcomes for research hypothesis: H1 and H2
The first hypothesis of this study was that there was a statistically significant
relationship between patients’ individual characteristics and whether or not they would talk
with their physician about a prescription drug prompted by DTC advertisement. The
second hypothesis of this study was that there was a statistically significant relationship
between patients’ personal beliefs and whether or not they would talk with their physician
about a prescription drug prompted by DTC advertisement. We used “visit for prescription
drug” as the dependent variable and variables from the five groups of factors
(demographics, socioeconomics, health status, market factor, and personal belief) as
independent variables to test the two hypotheses. The findings of logistic regression
analyses are presented as follows (see Table 9).

a. Effect of demographic factors
We found no evidence of association between visit for prescription drug after
seeing or hearing a DTC advertisement and any demographic factors (race, gender, age,
and marital status).
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b. Effect of socioeconomic factors
We also found no evidence of association between visit for prescription drug after
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education,
and prescription drug coverage).

c. Effect of health status factors
The odds of visiting for prescription drug for patients on regular medications were
1.6 times as high as the odds for those who were not on regular medications (p < 0.0001).
Patients with depression (p = 0.016) and patients with anxiety (p = 0.028) were more likely
to visit to discuss prescription drug after seeing or hearing a DTC advertisement than those
without such disease conditions. (Table 9.)

d. Effect of personal beliefs
Three variables measuring subjective norms showed significant associations with
the dependent variable (“visit for prescription drug”). Two of these variables measured
information source utilization. We found that visiting for prescription drug after seeing or
hearing a DTC advertisement was associated with the frequency of getting health
information from a physician. Specifically, a patient who often (p = 0.009) consulted a
physician had a higher chance to visit for prescription drug than those who never did so.
Patients who often (p = 0.014) or sometimes (p = 0.006) consulted a pharmacist had a
higher chance to be prompted by DTC advertisements to visit their physician to discuss a
prescription drug than those who never consulted a pharmacist. The odds of visiting for
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prescription drug for patients who viewed media as the most important source prompting
them to talk with their physician were almost 11 times as high as those who did not. (p <
0.0001) (Table 9.)
Patients’ attitudes towards DTC advertising demonstrated strong association with
their behaviors of visiting for prescription drug. Those who somewhat agreed (p < 0.0001)
or strongly agreed (p < 0.0001) that DTC advertisements increased awareness of new
treatment were much more likely to visit to discuss prescription drugs than those who
strongly disagreed. At the same time, the odds of another perceived benefit, better
discussion with health professionals, were also significantly different between the
somewhat agree/strongly-agree groups and the strongly-disagree group. Those who
somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were more likely to visit for
prescription drug after seeing or hearing a DTC advertisement than those who strongly
disagreed.
No evidence of association was found between visit for prescription drug after
seeing or hearing a DTC advertisement and perceived barrier or perceived severity. (Table
9.)

e. Effect of market factors
Advertisement attentiveness was strongly associated with the dependent variable
(“visit for prescription drug”). (p < 0.0001) In this study, patients with a high level of
advertisement attentiveness were defined as those who suffered from multiple chronic
conditions that have attracted substantial DTC advertising expenditure. Patients with high
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(p = 0.003) or very high (p < 0.0.001) advertisement attentiveness were more likely to visit
their physician for prescription drug after seeing or hearing a DTC advertisement than
those with very low advertisement attentiveness. (Table 9.)

3.2.3 Summary of model results for hypothesis: H1 and H2
The results of the logistic regression analysis supported our first hypothesis that
there was a statistically significant relationship between patients’ individual characteristics
and whether or not they would talk with their physician about a prescription drug prompted
by DTC advertisement. Specifically, patients on regular medications, patients with
depression or anxiety, or patients with high advertisement attentiveness were more likely
to visit their physician to discuss a prescription drug after seeing or hearing DTC
advertisements. The results of the regression analysis also supported our second hypothesis
that there was a statistically significant relationship between patients’ personal beliefs and
whether or not they would talk with their physician about a prescription drug prompted by
DTC advertisement. Patients who viewed media as the most important source prompting
them to talk with their physician, patients who often got health information from a
physician or a pharmacist, and those who had positive attitudes towards DTC
advertisements were more likely to visit their physician to discuss a prescription drug as a
result of DTC advertisements.

4. Outcomes on visit to discuss new health condition
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4.1. Bivariate analyses
Pearson chi square analyses showed that race, marital status, income, prescription
drug coverage, and diabetes were not associated with visit for new condition. Hence, these
five variables were excluded from multivariate analyses. All other independent variables
were associated with the dependent variable. The results of Pearson chi-square tests were
shown in Table 8.

4.2 Mutivariate analyses
4.2.1. Model evaluation
After running stepwise logistic regression, only eight variables stayed in the model.
The variables with significant effects were listed in Table 10. Hosmer and Lemeshow’s
Goodness-of-fit test statistic (Hosmer et al., 2000) was much greater than 0.05 (p= 0.51). It
suggested no significant difference between the observed and model-predicted values of
the dependent variable. Therefore, the model’s estimates fitted the data at an acceptable
level. Regression results indicated the overall model was statistically reliable in
distinguishing between visit for new condition and no visit for new condition. (-2 log
Likelihood = 1699.66; Chi-square = 493.9, df = 18, p < 0.0001). The model correctly
classified 96.5% of those in the “no visit” and 23.9% of those in the “visit” category.

4.2.2 Model outcomes for research hypothesis: H3 and H4
The third hypothesis of this study was that there was a statistically significant
relationship between patients’ individual characteristics and whether or not they would talk
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with their physician about a new health concern prompted by DTC advertisement. The
fourth hypothesis of this study was that there was a statistically significant relationship
between patients’ personal beliefs and whether or not they would talk with their physician
about a new health concern prompted by DTC advertisement. We used “visit for new
condition” as the dependent variable and variables from the five groups of factors
(demographics, socioeconomics, health status, market factor, and personal belief) as
independent variables to test the two hypotheses. The findings of logistic regression
analyses are presented as follows: (see Table 10.)

a. Effect of demographic factors
We found no evidence of association between visit for new condition after seeing or
hearing a DTC advertisement and any demographic factors (race, gender, age, and marital
status).

b. Effect of socioeconomic factors
We also found no evidence of association between visit for new condition after
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education,
and prescription drug coverage).

c. Effect of health status factors
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Patients with arthritis (p < 0.0001) and patients with anxiety (p < 0.0001) were
more likely to visit for new condition after seeing or hearing a DTC advertisement than
those without such disease conditions. (Table 10.)

d. Effect of personal beliefs
There were three variables measuring subjective norms that showed significant
effects on the dependent variable (“visit for new health condition”). Two variables
measured information source utilization. We found that visiting for new condition after
seeing or hearing a DTC advertisement was associated with the frequency of getting health
information from a pamphlet in a physician's office or waiting room (p < 0.0001).
Specifically, patients who often (p < 0.0001) got health information from pamphlets had a
higher chance to visit their physician for new condition than those who never did so.
Visiting for new condition after seeing or hearing a DTC advertisement was also
associated with the frequency of getting health information from family and friends (p =
0.02). However, no significant differences were found between the “never” group and any
other groups. Odds of visiting for new condition for the patients who viewed media as the
most important source prompting them to talk with their physician were almost 5 times as
high as those who did not. (p < 0.0001) (Table 10.)
Patients’ attitudes towards DTC advertising demonstrated strong association with
their behaviors of visiting for new condition. Those who somewhat agreed (p = 0.001) or
strongly agreed (p < 0.0001) that DTC advertisements increased awareness of new
treatments were much more likely to visit for new condition than those who strongly
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disagreed. At the same time, the odds of another perceived benefit, better discussion with
health professionals,

were

also

significantly

different between

the

somewhat

agree/strongly-agree groups and the strongly-disagree group. (p < 0.0001) Those who
somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were much more likely to
visit for new condition after seeing or hearing a DTC advertisement than those who
strongly disagreed. Moreover, believing that DTC advertisements did not provide
information on risks and benefits in a balanced manner was negatively associated with
patient’s health behavior of visiting for new condition. (p = 0.037).

However, no

significant differences were found between the strongly-disagree group and any other
groups. No evidence of association was found between visit for new condition after seeing
or hearing a DTC advertisement and perceived severity. (Table 10.)

e. Effect of market factors
There was no evidence of association between visit for new condition after seeing
or hearing a DTC advertisement and advertisement attentiveness.

4.2.3 Summary of model results for hypothesis: H3 and H4
The results of the logistic regression analysis supported our third hypothesis that
there was a statistically significant relationship between patients’ individual characteristics
and whether or not they would talk with their physician about a new health concern
prompted by DTC advertisement. Specifically, patients with arthritis or anxiety were more
likely visit their physician to discuss a new health concern after seeing or hearing DTC
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advertisements. The results of the regression analyses also supported our fourth hypothesis
that there was a statistically significant relationship between patients’ personal beliefs and
whether or not they would talk with their physician about a new health concern prompted
by DTC advertisement. Patients who viewed media as the most important source
prompting them to talk with their physician, patients who often got health information
from family and friends, or from a pamphlet in a doctor’s office or waiting room, and those
who had positive attitudes towards DTC advertisements were more likely to visit their
physician to discuss a new health concern as a result of DTC advertisements.

5. Outcomes on visit to discuss treatment change
5.1. Bivariate analyses
Pearson chi square analyses showed that marital status and income were not
associated with visit for treatment change. Hence, marital status and income were excluded
from multivariate analyses. All other independent variables were associated with the
dependent variable (Table 8).

5.2 Mutivariate analyses
5.2.1. Model evaluation
After running stepwise logistic regression, ten variables stayed in the model (Table
11). Hosmer and Lemeshow’s Goodness-of-fit test statistic (Hosmer et al., 2000) was
much greater than 0.05 (p= 0.80). Regression results indicated the overall model was
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statistically reliable in distinguishing between visit for treatment change and no visit for
treatment change. (-2 log Likelihood = 1621.48; Chi-square = 606.50, df = 23, p < 0.0001).
The model correctly classified 96.8% of those in the “no visit” and 32.1% of those in the
“visit” category.

5.2.2 Model outcomes for research hypothesis: H5 and H6
The fifth hypothesis of this study was that there was a statistically significant
relationship between patients’ individual characteristics and whether or not they would talk
with their physician about change in treatment prompted by DTC advertisement. The sixth
hypothesis of this study was that there was a statistically significant relationship between
patients’ personal beliefs and whether or not they would talk with their physician about
change in treatment prompted by DTC advertisement. We used “visit for treatment
change” as the dependent variable and variables from five groups of factors
(demographics, socioeconomics, health status, market factor, and personal belief) as
independent variables to test the two hypotheses. The findings of logistic regression
analyses are presented as follows. (see Table 11.)

a. Effect of demographic factors
Race was the only demographic factor associated with patient’s visit for treatment
change. Visits for treatment change were more likely to happen among black patients than
among patients of races other than black or white. (p = 0.001). No difference was found
between white patients and those from other races. (Table 11.)
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b. Effect of socioeconomic factors
We found no evidence of association between visit for treatment change after
seeing or hearing a DTC advertisement and any socioeconomic factors (income, education,
and prescription drug coverage).

c. Effect of health status factors
The odds of visit to discuss treatment change for patients on regular medications
were 2.1 times as high as the odds for those who were not on regular medications (p <
0.0001). Patients with anxiety (p = 0.003) were more likely to visit for treatment change
after seeing or hearing a DTC advertisement than those without anxiety. (Table 11.)

d. Effect of personal beliefs
There were three variables measuring subjective norms that showed significant
effects on the dependent variable (“visit for treatment change”). Two variables measured
information source utilization. We found that visit for treatment change after seeing or
hearing a DTC advertisement was associated with the frequency of getting health
information from Internet websites (p = 0.037). Specifically, patients who often (p = 0.008)
searched Internet web sites for health information were more likely to visit their physician
for treatment change than those who never did so. Patients who often (p = 0.004) or
sometimes (p = 0.044) consulted a pharmacist were more likely to be prompted by DTC
advertisements to visit their physician for treatment change than those who never consulted
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a pharmacist. The odds of visiting for treatment change for patients who viewed media as
the most important source prompting them to talk with their physician were almost 5 times
as high as those who did not. (p < 0.0001) (Table 11.)
Patients’ attitudes towards DTC advertising demonstrated strong association with
their behaviors of visiting for treatment change. Those who somewhat agreed (p = 0.029)
or strongly agreed (p = 0.0001) that DTC advertisements led to increased awareness of
new treatment were much more likely to visit for treatment change than those who strongly
disagreed. At the same time, the odds of another perceived benefit, better discussion with
health professionals,

were

also

significantly

different between

the

somewhat

agree/strongly-agree group and the strongly-disagree group. (p < 0.0001) Specifically,
those who somewhat agreed (p < 0.0001) or strongly agreed (p < 0.0001) were much more
likely to visit for treatment change after seeing or hearing a DTC advertisement than those
who strongly disagreed. (p < 0.0001). Moreover, believing that DTC advertisements made
one less confident with physician’s judgment was negatively associated with the patients’
health behavior of visiting for new condition. (p = 0.034).

However, a significant

difference only showed between strongly-disagree group and somewhat-agree group. (p =
0.007) No evidence of association was found between visit for treatment change after
seeing or hearing a DTC advertisement and perceived severity. (Table 11.)

e. Effect of market factors
Advertisement attentiveness was strongly associated with the dependent variable
(“visit for treatment change”). (p < 0.0001) Patients with high levels of advertisement
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attentiveness were defined as those who suffered from multiple chronic conditions that
have attracted substantial DTC adverting expenditure. Patients with high (p < 0.0001) or
very high (p < 0.0001) advertisement attentiveness were more likely to visit to discuss
treatment change than those with very low advertisement attentiveness. (Table 11.)

5.2.3 Summary of model results for hypothesis: H5 and H6
The results of the logistic regression analysis supported the fifth hypothesis that
there was a statistically significant relationship between patients’ individual characteristics
and whether or not they would talk with their physician about change in treatment
prompted by DTC advertisement. Specifically, patients on regular medications, black
patients, patients with anxiety, and patients with high advertisement attentiveness were
more likely to visit their physician to discuss change in treatment after seeing or hearing
DTC advertisements. The results of the regression analysis also supported our sixth
hypothesis that there was a statistically significant relationship between patients’ personal
beliefs and whether or not they would talk with their physician about change in treatment
prompted by DTC advertisement. Patients who viewed media as the most important source
prompting them to talk with their physician, patients who often got health information
from Internet or a pharmacist, and those who had positive attitudes towards DTC
advertisements were more likely to visit their physician to discuss change in treatment as a
result of DTC advertisements.
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CHAPTER 5
DISCUSSION
Based on a conceptual framework, we built three regression models in order to
identify the strongest predictors of DTC-prompted physician visits. The dependent
variables of the three regression models were “visit for prescription drug”, “visit for new
condition”, and “visit for treatment change”. In our study, if an independent variable was
found to be significantly related to all three dependent variables, it was deemed a strong
predictor of DTC-prompted visits. The three dependent variables were similar in that they
measured DTC advertisements’ influence on patients’ physician visit behavior. They
differed in that they measured physician visits for different purposes

Strongest predictors of DTC-prompted visits
We found that out of all independent variables, only five variables consistently
showed significant effects on the three dependent variables after adjusting for other
variables. They were: 1) taking medication on regular basis, 2) anxiety, 3) viewing media
as the most important source prompting one to talk with physician, 4) believing that DTC
advertisements increased awareness of new treatment, and 5) believing that DTC
advertisements improved discussion with health professionals. Therefore, these five
variables were considered to be the strongest predictors for DTC-prompted physician
visits.
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Taking prescription drugs on a regular basis was one of the strongest predictors of
DTC-prompted visits. It supported the hypothesis that patients with chronic conditions
potentially treatable by the advertised drugs would be interested in the DTC
advertisements and visit their physician to request or discuss advertised drugs (Mintzes et
al., 2003). Anxiety was the only chronic condition showing significant association with all
types of physician visits, though we also found patients with two other chronic diseases,
depression and arthritis, were more likely to be prompted by DTC advertisements to visit
their physician for two of the three types of visits. The results were consistent with other
research outcomes (Sumpradit, 2002; Mintzes et al., 2003). The significant effects could be
attributed to the similar characteristics that these disease conditions shared, such as being
chronic, common, highly symptomatic, troublesome to patients, and treated with drugs
with high annual spending on DTC advertising (NIHCM, 2001). In addition, anxiety could
have an additional, psychological effect in influencing patients’ physician visit behavior.
Patients with anxiety are more likely to worry, especially about their health status.
Therefore, they would be more sensitive to the symptoms described in the DTC
advertisements, wondering if they had similar symptoms. As a result, they may be
prompted to visit their physicians.
The major variables adopted from the Theory of Reasoned Action and Health
Belief Model were strong determinants for each type of DTC-prompted physician visit.
These personal belief variables included subjective norm, perceived benefit, and perceived
barrier. In our study, patients who viewed media as the most important source prompting
them to talk with their physicians were much more likely to visit their physician than those
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who viewed non-media as more important referent sources. Mintzes also reported similar
results that those with greater reliance on advertising requested more advertised drugs
(Mintzes et al., 2003). Two of the other strongest predictors were believing that DTC
advertisements increased awareness of new treatment (perceived benefit) and believing
that DTC advertisements improved discussion with health professionals (perceived
benefit). Our findings agreed with Sumpradit’s study results, which showed positive
association between positive attitude toward DTC advertisements and consumer’s
willingness of talk with physicians about advertised drugs (Sumpradit et al., 2002).
Advertisement attentiveness was significantly related to visit for prescription drug and visit
for treatment change but not to visit for new condition. Our assumption was that
advertisement attentiveness exists only when patients have been told by health care
professionals that they suffer from conditions and when these conditions are potentially
treatable by advertised drugs. A new condition is, by definition, one that a patient has not
yet discussed with a health professional. So conceptually, visit for new condition would
not be related with advertisement attentiveness as we measured it. Because advertising
attentiveness was significantly related to both visit for prescription drug and visit for
treatment change, and because conceptually it should not be related to visit for new
condition, we also deemed advertisements attentiveness as one of the strongest predictors
for physician visits.
This study contributed to the literature of how DTC advertising influenced patients’
health behavior in several ways. First, it updated our knowledge about the consequences of
DTC advertisements, such as physician visits and attitudes towards advertisements. In
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addition, our study provided a conceptual framework of how DTC advertisements
influenced patients’ physician visits for different purposes while most previous studies
only examined one type of physician visit. For instance, Mintzes (Mintzes et al, 2002) and
Pyrot (Pyrot et al, 1998) analyzed the factors affecting patients’ request behavior but failed
to address other types of physician visits, such as visit to discuss new health conditions or
information on prescription drug. Finally, this study tested the conceptual framework with
a nationally representative sample. Most previous studies were limited in terms of their
sample size, location, or differences in nationality and healthcare system.

Implications
The study had important practical implications to pharmaceutical marketers. Some
pharmaceutical manufacturers have apparently believed that that selling to the widest
possible market is the likeliest path to success. However, this “take-all-customers”
approach was not very productive. It was hard to generate cost effective sales when
delivering promotional information to the broad audience without targeting individual
differences. A more efficient way may be to narrow marketing focus and customize
product messages before disseminating DTC advertisements. Accurate target market
selection is crucial to productive marketing efforts. To achieve this, a target market must
be a narrowly defined consumer group consisting of individuals with specialized
characteristics and having strong desires for what the marketer can offer. DTC advertising
campaigns may have been less cost-effective because pharmaceutical marketers did not
aim their efforts at appropriate customer groups.
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Marketers can use our findings to accurately identify target markets. Our study
revealed that patients regularly taking medications and those who had anxiety were more
likely to respond to DTC advertising. Hence, as better potential customers, they could be
identified as important target markets for specialized DTC advertising. With a higher
probability of DTC-prompted physicians visits, equal expenditures on marketing
promotions could achieve higher returns on investments from these patient groups.
Advertisement attentiveness is a proxy variable based on patients’ chronic
conditions and annual DTC spending on these conditions. Pharmaceutical companies could
target more marketing to those consumers who have multiple, heavily advertised chronic
conditions. Related information could be acquired from medical records, regional or
national marketing data sources, i.e. IMS or Scott-Levin databases.
Personal beliefs about DTC advertisements were also strong predictors for all
types of physician visit behaviors. According to our findings, patients with positive
attitudes toward DTC advertisements or patients viewing media as the most important
source prompting them to talk with physicians were more likely to respond to
advertisements. Pharmaceutical marketers may be able to identify patients on regular
medications, those having anxiety, and those with high potential advertisement
attentiveness from their medical records or pharmacy claims databases. However, it is not
possible to get information on patients’ personal beliefs from these sources. Therefore, in
order to target these consumers, pharmaceutical marketers could develop interactive tactics
to acquire information with advanced Internet technologies. For instance, marketers could
post personal belief questions on web sites for medical information or pharmaceutical
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products. They could then develop direct response technologies on the Internet to send
customized letters and brochures to respondents based on the answers that respondents
give to questions about their personal beliefs.

Limitations
Several limitations should be noted when considering our results.
First, we lacked information on how many physician visits each patient had made
as a result of DTC advertisements and how appropriate or necessary the physician visits
were. Though Weissman’s study has reported that no worse heath outcomes were found
among patients who visited their physician for advertised drugs than those who did not,
further study still needs to examine DTC advertisements’ long-term effects on health
outcomes (Weissman et al., 2003).
Second, our data on medication utilization and health conditions were collected by
survey. Therefore, they may be subject to self-report bias. However, previous studies have
evaluated the accuracy and reliability of self-reported medication use and chronic
conditions. These studies revealed consistency between database information and selfreport results (Boudreau et al. 2003; Brown et al., 1992; West et al., 1995). For example,
Boudreau’s study explored the accuracy of self-reported use of commonly used
medications among older women (n = 403). Pharmacy records of statin, antihypertensive,
and antidepressant medication utilizations were used as the “gold standard” to compare
with patients’ interview data. Information on the brand name, strength, directions for use
indications for use, and start and stop dates were collected for comparison. The study
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showed that the sensitivity of self-reported data ranged from 79% to 92% for
antihypertensive use, from 67% to 93% for statin use, and from 44% to 66% for
antidepressant use. Specificity was high among all drug classes, ranging form 91% to
100%. Recall for recent medication use (previous 6-month period) revealed higher
accuracy than older periods (previous 2-year and 8-year period).
Third, we calculated and scaled patients’ advertisement attentiveness based on
assumptions. We supposed that all patients had an equal chance of viewing DTC
advertisements and that only patients with conditions that were potentially treatable by the
promoted drugs would be interested in the DTC advertisements. However, this could be
confounded by other factors, such as satisfaction with current treatments, accessibility to
cable TV, content of DTC advertisements, or geographic locations.
Fourth, other external factors may influence the outcomes. Our study analyzed
the influence of DTC advertising on physician visits based on the differences in personal
characteristics, including demographics, socioeconomics, personal beliefs, health status,
and market influence on patients. Other external factors, such as type of health insurance,
patients’ relationship with their physicians, satisfaction with their current treatments, may
also interact with DTC advertisements to change patients’ physician visit behaviors. Since
we used secondary data for analyses, we lacked information on these external factors. It
would be helpful in future research to add these external factors for analysis.
Fifth, our study did not examine the interaction effects between independent
variables. For instance, income may interact with age’s influence on physician visit. In the
high-income population, old patients maybe more likely to visit physician than the younger
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patients, while in the low-income population, the old patients maybe less likely to visit
physician than the younger ones. Similar situation may also exist among other
demographic or socioeconomic factors. Hence, future research should also consider the
interaction effects for study.
Sixth, although we have described how patients’ attitudes and personal beliefs can
be measured using Internet interactive technologies, it is more difficult to use these
practices to target patients using the more traditional media such as

TV or radio.

Demographic information, such as age or race, would be more useful to apply to target
consumers on TV or radio. Studies that examine the sole effects of demographic factors on
physician visits are recommended for future research.

Conclusion
Our nationally representative study found multiple factors that were associated
with different types of physician visits prompted by DTC advertisements. According to
these factors, we decided what kinds of patient would be most likely to talk to their
physicians as a result of DTC advertisements. Patients on regular medications, those with
anxiety, those with high advertisement attentiveness, patients who viewed media as the
most important source prompting them to talk with their physician, and patients with
positive attitudes toward DTC advertisements consistently showed significant relationships
with each type of physician visit. Patients with these characteristics were more likely to
talk to their physicians when prompted by DTC advertisements.
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Table 1.

U.S. Promotional Spend by Direct-to-Consumer Advertising, 2003

Promotion Spend
(U.S. Millions $)

1996 1997 1998 1999 2000 2001 2002 2003

Direct-to-Consumer 791
(DTC)

1,069 1,317 1,848 2,467 2,679 2,638 3,235

Note: Direct-to-Consumer (DTC) expenditures include advertising spending on television,
magazines and newspapers, on radio and outdoors.

Source: IMS Health, Integrated Promotional ServicesTM and CMR, 6/2004
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Table 2.

Year 1998-2000 Average Return-on-Investments by Brand Revenue for
Different Promotion Tactics
Return-On-Investment (ROI) of Promotions
(1998-2000)

Revenue Level

DTC
advertising

Detailing

Journal
Advertising

Physician
Meeting &
Events

$25 - $100MM

$0.0

$1.0

$7.2

$0.1

$100 -$500MM

$0.2

$2.1

$4.2

$3.6

$500+MM

$1.3

$11.6

$12.2

$11.7

ROI: Return-on-Investment
MM: Million

Source: Return on Investment Analysis of Pharmaceutical Promotion (RAPP), 2002
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Table 3.

List of Variables and Measurements
Dimension

Variable

Measurement

Outcome (1)

Visit for
Prescription drug

Q448* Has an ad for a prescription drug ever
prompted you to talk to a doctor about a
prescription drug for yourself?

Outcome (2)

Visit for
New condition

Q452 Has an ad for a prescription drug ever
prompted you to talk to a doctor about a medical
condition, illness, or other health concern of
your own that you had not discussed with a
doctor before?

Outcome (3)

Visit for
Treatment change

Q456 Has an ad for a prescription drug ever
prompted you to talk to a doctor about a possible
change in treatment for a medical condition or
illness that you already had?

Personal
Beliefs

Subjective Norm
1) Source importance

Q608 Which one of the sources is most
important in prompting you to talk to your
doctor? (Media or non-media)

2) Source utilization

Q265 How often do you get information about
health from (source)? (TV/radio, internet,
newspapers or magazines, family and friends, a
pharmacist, pamphlets in a doctor’s office or
waiting room, a doctor)

Perceived Benefit
1) Awareness of
treatments

Q410-1 (DTC ads) made me aware of treatment
that I did not know about

2) Patient-physician
communication

Q410-5 (DTC ads) helped me to have better
discussions about my health with a health
professional

Perceived Barrier
1) Unbalanced
Information

Q410-3 (DTC ads) did not provide information
on risks and benefits in a balanced manner

2) Physician’s
Authority

Q410-4 (DTC ads) made me less confident in
my doctor’s judgment
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Perceived Severity
Overall health
Health
Status Factors

Socioeconomic
Factors

Healthcare service
utilization
Disease conditions

Q255 Have you ever been told by a doctor that
you have any of the following conditions?
(Seven chronic conditions: diabetes, depression,
arthritis, allergies, high cholesterol, asthma or
other problems with lungs, and anxiety)

Medication use

Q230 Do you currently take any prescription
drug on a regular basis?

Prescription insurance
coverage

Q820 Does your insurance or health plan pay for
all, some, or none of the costs of Rx drugs you
get at the pharmacy or through the mail?

Education

Q110 What is the highest level of education you
have completed or the highest degree you have
received?
Q142 Which of the following income categories
best describes your total 2000 household income
before taxes?

Income

Market Factors

Demographic
Factors

Note:

Q214 Overall, how would you describe your
health?
Q218 How long has it been since the last time
your saw a doctor where you talked about a
condition?

Advertisement
attentiveness

The
proxy
value
of
“advertisement
attentiveness” for each respondent was based on
the DTC spending on the drugs used to treat the
respondent’ chronic conditions

Advertisement
information utilization

Q265c How often do you get information about
health care from ads on TV or radio, in
newspapers or magazines?

Gender

Q210 Respondent sex

Race

Q122 Do you consider yourself (race)?

Age

Q104 What is your year of birth?

Marital status

Q109 Which of these best describes your
marital status?

* Q # represents questions number in the questionnaire.
** See table 4.
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Table 4.

DTC Advertisement Spending by Therapeutic Class in 2000
Diseases

DTC spending ($Million)

Diabetes
Depression
Athritis
Allergies
Athma/lung problem
Anxiety
High Cholesterol

76.10
115.10
265.00
252.00
279.40
77.30
211.20

Source: National Institute of Healthcare Management (NIHCM) Foundation, Prescription
Drugs and Mass Media Advertising: 1999 - 2000, Med Ad News and ScottLevin Year 2000 Prescription Audit Data
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Table 5. (1)

Descriptive Analyses: Demographic and Socioeconomic Factors
Respondent characteristics

N

%

Gender
Female
Male

1560
1440

48.0
52.0

Race
White
Black
Other race

2363
295
295

80.0
10.0
10.0

Age
18-34
35-64
65+

834
1591
575

27.8
53.0
19.2

Marital Status
Non-single (e.g. married, living with a partner)
Single (e.g. divorced, separated, window)

1726
1257

57.9
42.1

Socioeconomic Factors
Education
Less than high school graduate
High school graduate or equivalent (e.g., GED)
Completed some college, but no degree
College graduate (e.g., B.A., A.B., B.S.)
Graduate school level

259
883
683
777
384

8.7
29.6
22.9
26.0
12.9

Income
Poor (Less than $15,000)
Lower income ($15,000 to $29,999)
Middle income ($30,000 to $74,999)
High income ($75,000 or more)

319
355
1409
606

11.9
13.2
52.4
22.5

Prescription Drug Coverage by Insurance
All
Some
None

408
1929
587

14.0
66.0
20.0

Demographic factors
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Table 5. (2)

Descriptive Analyses: Health Status Factors
Respondent characteristics

N

%

Within the last three months
More than three months, but less than one year ago
More than one year ago

1610
754
620

54.0
25.2
20.8

Whether on any medication
Do you currently take any prescription drug on a regular
basis?
Yes
No

1588
1404

53.1
46.9

228
2764

7.6
92.4

378
2614

12.6
87.4

631
2356

21.1
78.9

822
2163

27.5
72.5

634
2341

21.3
78.7

361
2632

12.1
87.9

327
2662

10.9
89.1

Use of healthcare services
How long has it been since you last saw a doctor where
you talked about health condition or concern of your own?

Different disease conditions
Been told have condition:
Diabetes
Yes
No
Depression
Yes
No
Arthritis
Yes
No
Allergies
Yes
No
High cholesterol
Yes
No
Asthma or other problems with your lungs
Yes
No
Anxiety
Yes
No
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Table 5. (3)

Descriptive Analyses: Market Factors
Respondent characteristics

N

%

781
902
679
626

26.1
30.2
22.7
21.0

726
820
170
1227

24.7
27.9
5.7
41.7

Advertisements Information Utilization
Get health care information from: Advertisements on
TV or radio, in newspapers or magazines
Often
Sometimes
Hardly Ever
Never
Advertisement attentiveness
Very high
High
Low
Very low
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Table 5. (4)

Descriptive Analyses: Personal Beliefs
Respondent characteristics

N

%

Subjective Norm
1) Referent Source:
Which one of the sources is most important in prompting
you to talk to your doctor?
Non-media source (i.e. doctors, pharmacists, friends)
Media source (i.e. TV, radio, paper, Internet)

2653
279

90.5
9.5

452
933
800
795

15.2
31.3
26.8
26.7

254
521
527
1692

8.5
17.4
17.6
56.5

540
955
733
751

18.1
32.1
24.6
25.2

603
1108
733
536

20.2
37.2
24.6
18.0

884
1122
623
313

30.0
38.1
21.2
10.6

2) Source utilization
How often do you get information about health from…?
Television or radio, not including ads
Often
Sometimes
Hardly Ever
Never
Internet websites
Often
Sometimes
Hardly Ever
Never
Newspapers or magazines, not including ads
Often
Sometimes
Hardly Ever
Never
Family and friends
Often
Sometimes
Hardly Ever
Never
A doctor
Often
Sometimes
Hardly Ever
Never
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Table 5. (5)

Descriptive Analyses: Personal Beliefs (continued)
N

%

Pamphlets in a doctor’s office or waiting room
Often
Sometimes
Hardly Ever
Never

379
1047
843
709

12.7
35.2
28.3
23.8

A pharmacist
Often
Sometimes
Hardly Ever
Never

335
734
856
1042

11.3
24.7
28.9
35.1

673
1100
383
777

22.9
37.5
13.1
26.5

632
946
434
909

21.6
32.4
14.9
31.1

Respondent characteristics
2) Source utilization (continued)
How often do you get information about health from…?

Perceived Benefit
1) Awareness of treatments: DTC advertisements made
me aware of treatment that I did not know about
Strongly Agree
Somewhat Agree
Somewhat Disagree
Strongly Disagree
2) Patient-physician relationship: DTC advertisements
helped me to have better discussion s about my health
with a health professional
Strongly Agree
Somewhat Agree
Somewhat Disagree
Strongly Disagree
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Table 5. (6)

Descriptive Analyses: Personal Beliefs (continued)
Respondent characteristics

N

%

520
780
677
906

18.0
27.1
23.5
31.4

139
317
608
1823

4.8
11.0
21.1
63.1

662
959
888
354
124

22.2
32.1
29.7
11.9
4.2

Perceived Barrier
1) Unbalanced Information: DTC advertisements did not
provide information on risks and benefits in a balanced
manner
Strongly Agree
Somewhat Agree
Somewhat Disagree
Strongly Disagree
2) Physician’s Authority: DTC advertisements made me
less confident in my doctor’s judgment
Strongly Agree
Somewhat Agree
Somewhat Disagree
Strongly Disagree
Perceived Severity
Overall Health
Overall, how would you describe your health excellent,
very good, good, fair or poor?
Excellent
Very good
Good
Fair
Poor

93
Table 6.

Summary of Dependent Variables and Intervention
Variable of Interest

N

Outcome (1): Has an ad for a prescription drug ever prompted
you to talk to a doctor about a prescription drug for yourself? *
Yes
801
No
2177
Outcome (2): Has an ad for a prescription drug ever prompted
you to talk to a doctor about a medical condition, illness, or other
health concern of your own that you had not discussed with a
486
doctor before? *
Yes
2489
No

%
26.9
73.1

16.3
83.7

Outcome (3): Has an ad for a prescription drug ever prompted
you to talk to a doctor about a possible change in treatment for a
medical condition or illness that you already had? *
Yes
518
No
2455

17.4
82.6

Intervention: Have you ever seen or heard an advertisement for
a prescription drugs in the past 12 months?
Yes
No

85.8
14.2

2563
424

* Only those who have ever seen or heard an advertisement for a prescription drugs in the
past 12 months were asked about their physician visit. Those who had not seen or heard an
advertisement were coded as ‘no’.
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Table 7.

Multicollinearity Tests
Independent Variables
Race
Age
Education
Income
Marital status
Prescription drugs coverage?
Healthcare service utilization
Medication usage
Diabetes
Depression
Arthritis
Allergies
High cholesterol
Asthma or other problems with your lungs
Anxiety
Advertisement information utilization
Advertisement attentiveness
Perceive benefit: aware of treatments
Perceive benefit: better discussions with professional
Information source importance
Source utilization: TV or radio, not including ads

Collinearity Statistics*
Tolerance
VIF
.913
1.095
.673
1.485
.707
1.414
.644
1.552
.848
1.179
.943
1.061
.769
1.300
.623
1.605
.868
1.152
.673
1.486
.505
1.979
.385
2.600
.491
2.039
.691
1.447
.703
1.423
.701
1.427
.159
6.279
.602
1.662
.586
1.707
.882
1.134

.721
Source utilization: Internet websites
.819
Source utilization: Newspapers or magazines, not including ads .736
Source utilization: Family and friends
.848
Source utilization: A pharmacist
.802
Source utilization: Pamphlets in a doctor's office/ waiting room .767
Source utilization: A doctor
.730
Perceived barrier: unbalanced information
.872
Perceived barrier: less confident in my doctor's judgment
.853
Perceived severity: overall health
.752

1.387
1.221
1.358
1.179
1.247
1.304
1.371
1.147
1.173
1.331
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Table 8.

Bivariate Analyses: Pearson Chi-square Tests
Independent variables

Visit for
Visit for
Visit for
prescription drug new condition treatment change

Demographics factors
Sex

***

**

***

*

ns

**

**
ns

*
ns

***
ns

Income

***
*

**
ns

*
ns

Prescription drug coverage

**

ns

*

Health service utilization

***

***

***

Regularly take medication

***

***

***

Disease condition: Diabetes

**

ns

***

Disease condition: Depression

***

***

***

Disease condition: Arthritis

***

***

***

Disease condition: Allergies

***

***

***

cholesterol

***

***

***

Disease condition: Asthma

***

**

***

Disease condition: Anxiety

***

***

***

Race
Age
Marital status
Socioeconomic factors
Education

Health status factor

Disease condition: High

Note: Significance level
*** < 0.0001
** < 0.05
* < 0.25
“ns” means no relationship between the independent variable and the dependent
variable.
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Independent variables
(Continued)

Visit for
Visit for
Visit for
prescription drug new condition treatment change

Market factors
Advertisement information utilization

***

***

***

Advertisement attentiveness

***

***

***

Referent source

***

***

***

Source utilization: Television or radio

***

***

***

Source utilization: Internet websites

***

***

***

Source utilization: Magazines or
newspaper

***

***

***

Source utilization: Family and friends

***

***

***

Source utilization: A pharmacist

***

***

***

Source utilization: Pamphlets

***

***

***

Source utilization: A doctor

***

***

***

Awareness of treatments

***

***

***

Patient-physician communication

***

***

***

Unbalanced information

***

***

***

Physician’s authority

***

***

***

Perceived severity: overall health

***

***

***

Personal beliefs

Note: significance level

*** < 0.001

** < 0.05

* < 0.25
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Table 9.

Logistic Regression Model (1): Factors Associated with Visiting a Physician
to Discuss a Prescription Drug Prompted by DTC Advertisements
Variables in Model

Odds
Ratio

95% CI
Sig.
Lower Upper

Health Status Factors
1) Whether taking any medication on regular basis?

1.61

1.25

2.08

2) Disease conditions:
Depression
Anxiety

1.64
1.57

1.10
1.05

2.44 0.016
2.33 0.028

1.20
1.26
0.50

0.000
2.37 0.003
2.25 0.000
1.49 0.598

0.000

Market Factors
Advertisement attentiveness:
Very high
High
Low
Very low (reference group)

1.69
1.68
.086
1.00

Personal Beliefs
-- Subjective Norm:
1) Source utilization: get health information from a
doctor
Often
Sometimes
Hardly Ever
Never (reference group)

1.99
1.58
1.20
1.00

1.19
0.96
0.71

0.009
3.32 0.009
2.59 0.71
2.05 0.50

2) Source utilization: get health information from a
pharmacist
Often
Sometimes
Hardly Ever
Never (reference group)

1.63
1.57
1.29
1.00

1.11
1.14
0.94

0.024
2.41 0.014
2.15 0.006
1.76 0.111
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3) Referent Source: media as most important source
prompting a patient to talk with doctor

10.87

-- Perceived Benefit:
1) Awareness of treatments: Rx ads made me aware
of treatment that I did not know
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

3.05
2.33
1.52
1.00

2) Patient-doctor relationship: Rx ads made me have
better discussion with professionals
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

7.47
5.46
2.24
1.00

7.35 16.08 0.000

1.95
1.52
0.92

0.000
4.76 0.000
3.56 0.000
2.50 0.101

.000
4.77 11.71 .000
3.54 8.41 .000
1.37 3.66 0.001
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Table 10.

Logistic Regression Model (2): Factors Associated with Visiting a Physician
to Discuss a New Health Condition Prompted by DTC Advertisements
Variables in Model

Odds
Ratio

95% CI
Lower Upper

Sig.

Health Status Factors
Disease conditions:
Arthritis
Anxiety

1.80
1.95

1.35
1.38

2.41
2.76

0.000
0.000

Personal Beliefs
-- Subjective Norm:
1) Source utilization: get health information from
family and friends
Often
Sometimes
Hardly Ever
Never (reference group)

1.54
1.08
0.91
1.00

0.99
0.70
0.58

2.41
1.65
1.44

0.02
0.055
0.734
0.697

2) Source utilization: get health information from a
pamphlet in a doctor's office or waiting room
Often
Sometimes
Hardly Ever
Never (reference group)
3) Referent Source: media as most important source
prompting a patient to talk with doctor
-- Perceived Benefit:
1) Awareness of treatments: Rx ads made me aware of
treatment that I did not know
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

2.66
1.29
1.25
1.00

1.70
0.86
0.81

4.16
1.95
1.91

0.000
0.000
0.219
0.316

4.78

3.53

6.49

.000

5.70
4.42
2.91

0.000
0.000
0.001
0.184

3.28
2.57
1.54
1.00

1.88
1.49
0.82

100
2) Patient-doctor relationship: Rx ads made me have
better discussion with professionals
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

5.13
4.17
2.29
1.00

3.00
2.46
1.26

8.79
7.06
4.18

0.000
0.000
0.000
0.007

-- Perceived Barrier:
Unbalanced information: Rx ads did not provide
information on risks and benefits in a balanced manner
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

0.81
0.97
1.36
1.00

0.54
0.68
0.96

1.22
1.38
1.93

0.037
0.312
0.866
0.089
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Table 11.

Logistic Regression Model (3): Factors Associated with Visiting a Physician
to Discuss a Change to New Treatment Prompted by DTC Advertisements
Variables in Model

Odds
Ratio

95% CI
Sig.
Lower Upper

Health Status Factors
Whether taking any medication on regular basis?

2.11

1.58

2.83

0.000

Disease condition: anxiety

1.73

1.21

2.48

0.003

Race
White
Black
Other races (reference group)

1.63
2.79
1.00

0.99
1.53

2.68
5.10

0.002
0.057
0.001

Market Factors
Advertisement attentiveness:
Very high
High
Low
Very low (reference group)

3.49
2.38
2.63
1.00

2.42
1.69
1.50

.000
5.04 0.000
3.35 0.000
4.61 0.001

1.15
0.82
0.66

0.037
2.54 0.008
1.61 0.422
1.34 0.724

1.21
1.01
0.75

0.010
0.004
0.044
0.737

Demographic Factors

Personal Beliefs
-- Subjective Norm:
1) Source utilization: get health information from
Internet websites
Often
Sometimes
Hardly Ever
Never (reference group)
2) Source utilization: get health information from a
pharmacist
Often
Sometimes
Hardly Ever
Never (reference group)

1.71
1.15
0.94
1.00

1.82
1.42
1.06
1.00

2.73
2.01
1.51
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3) Referent Source: media as most important incentive
source to talk with doctors
-- Perceived Benefit:
1) Awareness of treatments: Rx ads made me aware of
treatment that I did not know
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)
2) Patient-doctor relationship: Rx ads made me have
better discussion with professionals
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)
-- Perceived Barrier:
Unbalanced information: Rx ads made me less
confident in my doctor’s judgment
Strongly agree
Somewhat Agree
Somewhat Disagree
Strongly disagree (reference group)

4.87

2.43
1.72
1.30
1.00

6.66
5.01
2.97
1.00

1.08
1.66
1.35
1.00

3.53

6.72

0.000

1.47
1.06
0.74

0.001
4.02 0.001
2.80 0.029
2.29 0.366

0.000
3.89 11.41 0.000
2.96 8.49 0.000
1.65 5.33 0.000

0.63
1.15
0.99

0.034
1.84 0.784
2.39 0.007
1.82 0.056
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Figure 1.

Trends in Spending on Direct-to-Consumer Advertising

Source: Rosenthal et al., N Engl J Med Feb. 14, 2002, 346 (7): 498-505, S

Source: Rosenthal et al., N Engl J Med Feb. 14, 2002, 346 (7): 498-505
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Figure 2.

Conceptual Framework
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SPSS Syntax for model (1):
LOGISTIC REGRESSION VAR=q448b
/METHOD=FSTEP(COND) q210 q122 age q110 q142 q820b q218 q230 q255a1 q255a2 q255a3
q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi
q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214
/CONTRAST (q122)=Indicator /CONTRAST (age)=Indicator(1) /CONTRAST (q110)=Indicator
/CONTRAST (q142)=Indicator(1) /CONTRAST (q820b)=Indicator /CONTRAST (q218)=Indicator
/CONTRAST (adattent)=Indicator(1) /CONTRAST (q411b1)=Indicator /CONTRAST
(q411b5)=Indicator /CONTRAST (q265a1)=Indicator /CONTRAST (q265a2)=Indicator
/CONTRAST
(q265a4)=Indicator /CONTRAST (q265a5)=Indicator /CONTRAST
(q265a6)=Indicator /CONTRAST (q265a7)=Indicator /CONTRAST
(q265a8)=Indicator /CONTRAST (q411b2)=Indicator /CONTRAST
(q411b4)=Indicator /CONTRAST (q214)=Indicator
/CLASSPLOT
/PRINT=GOODFIT SUMMARY CI(95)
/CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) .
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SPSS Syntax for model (2):
LOGISTIC REGRESSION VAR=q452b
/METHOD=FSTEP(COND) q210 age q110 q218 q230 q255a1 q255a2 q255a3
q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi
q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214
/CONTRAST (age)=Indicator(1) /CONTRAST (q110)=Indicator
/CONTRAST (q218)=Indicator /CONTRAST (adattent)=Indicator(1) /CONTRAST
(q411b1)=Indicator /CONTRAST
(q411b5)=Indicator /CONTRAST (q265a1)=Indicator /CONTRAST (q265a2)=Indicator
/CONTRAST
(q265a4)=Indicator /CONTRAST (q265a5)=Indicator /CONTRAST
(q265a6)=Indicator /CONTRAST (q265a7)=Indicator /CONTRAST
(q265a8)=Indicator /CONTRAST (q411b2)=Indicator /CONTRAST
(q411b4)=Indicator /CONTRAST (q214)=Indicator
/CLASSPLOT
/PRINT=GOODFIT SUMMARY CI(95)
/CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) .
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SPSS Syntax for model (3):
LOGISTIC REGRESSION VAR=q456b
/METHOD=FSTEP(COND) q210 q122 age q110 q820b q218 q230 q255a1 q255a2 q255a3
q255a7 q255a8 q255a9 q255a11 q265a3 adattent q411b1 q411b5 q608medi
q265a1 q265a2 q265a4 q265a5 q265a6 q265a7 q265a8 q411b2 q411b4 q214
/CONTRAST (q122)=Indicator /CONTRAST (age)=Indicator(1) /CONTRAST (q110)=Indicator
/CONTRAST (q820b)=Indicator /CONTRAST (q218)=Indicator /CONTRAST
(adattent)=Indicator(1) /CONTRAST (q411b1)=Indicator /CONTRAST (q411b5)=Indicator
/CONTRAST (q265a1)=Indicator /CONTRAST (q265a2)=Indicator /CONTRAST
(q265a4)=Indicator /CONTRAST (q265a5)=Indicator /CONTRAST
(q265a6)=Indicator /CONTRAST (q265a7)=Indicator /CONTRAST
(q265a8)=Indicator /CONTRAST (q411b2)=Indicator /CONTRAST
(q411b4)=Indicator /CONTRAST (q214)=Indicator
/CLASSPLOT
/PRINT=GOODFIT SUMMARY CI(95)
/CRITERIA PIN(.05) POUT(.10) ITERATE(20) CUT(.5) .
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